株探米国株
日本語 英語
エドガーで原本を確認する
0001099219false00010992192024-10-302024-10-300001099219us-gaap:CommonStockMember2024-10-302024-10-300001099219us-gaap:SeriesAPreferredStockMember2024-10-302024-10-300001099219us-gaap:SeriesEPreferredStockMember2024-10-302024-10-300001099219us-gaap:SeriesFPreferredStockMember2024-10-302024-10-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549  
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 30, 2024
METLIFE, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
 
1-15787 13-4075851
(Commission File Number) (IRS Employer Identification No.)
200 Park Avenue, New York, NY 10166-0188
(Address of Principal Executive Offices) (Zip Code)
(212) 578-9500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 MET New York Stock Exchange
Floating Rate Non-Cumulative Preferred Stock,
Series A, par value $0.01
MET PRA New York Stock Exchange
Depositary Shares, each representing a 1/1,000th
interest in a share of 5.625% Non-Cumulative
Preferred Stock, Series E
MET PRE New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F MET PRF
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐



Item 2.02 Results of Operations and Financial Condition.
On October 30, 2024, MetLife, Inc. issued (i) a news release announcing its results for the quarter ended September 30, 2024 (the “Earnings Release”), a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, (ii) a Quarterly Financial Supplement for the quarter ended September 30, 2024 (the “Quarterly Financial Supplement”), a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference and (iii) a fact sheet setting forth its total assets under management as of September 30, 2024 (the "Total AUM Fact Sheet"), a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.
The Earnings Release and the Quarterly Financial Supplement are furnished and not filed pursuant to instruction B.2 of Form 8-K. The foregoing description of the Total AUM Fact Sheet is not complete and is qualified in its entirety by reference to the Total AUM Fact Sheet, which is filed as Exhibit 99.3.
Item 7.01 Regulation FD Disclosure.
On October 30, 2024, MetLife, Inc. issued a supplemental slide presentation for the quarter ended September 30, 2024, (the “Supplemental Slides”), a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference. The slides highlight information in MetLife, Inc.’s Earnings Release and Quarterly Financial Supplement, as well as other prior public disclosures. The Supplemental Slides are furnished and not filed pursuant to instruction B.2 of Form 8-K.
Item 8.01 Other Events.
The text of Item 2.02 above with respect to the Total AUM Fact Sheet is incorporated herein by reference.
2


Item 9.01 Financial Statements and Exhibits.

101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language)
104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)
3


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
METLIFE, INC.
By: /s/ Tamara L. Schock
Name: Tamara L. Schock
Title: Executive Vice President and
Chief Accounting Officer
Date: October 30, 2024
4
EX-99.1 2 ex991earningsreleasetables.htm EX-99.1 Document

Exhibit 99.1

mllogonewa22a.jpg
                    For Immediate Release İ Global Communications İ MetLife, Inc.


METLIFE ANNOUNCES THIRD QUARTER 2024 RESULTS
NEW YORK, October 30, 2024 - MetLife, Inc. (NYSE: MET) today announced its third quarter 2024 results.
Third Quarter Results Summary
•Net income of $1.3 billion, or $1.81 per share, compared to net income of $422 million, or $0.56 per share, in the third quarter of 2023.
•Adjusted earnings of $1.4 billion, or $1.95 per share, compared to adjusted earnings of $1.5 billion, or $1.97 per share, in the third quarter of 2023.
•Book value of $39.02 per share, up 33 percent from $29.34 per share at September 30, 2023.
•Book value, excluding accumulated other comprehensive income (AOCI) other than foreign currency translation adjustments (FCTA), of $54.72 per share, up 3 percent from $53.00 per share at September 30, 2023.
•Return on equity (ROE) of 20.2 percent.
•Adjusted ROE, excluding AOCI other than FCTA, of 14.6 percent.
•Holding company cash and liquid assets of $4.5 billion at September 30, 2024, which is above the target cash buffer of $3.0 - $4.0 billion.


"Despite lower variable investment income, MetLife demonstrated the financial attractiveness of our business in the third quarter, including an adjusted return on equity of 14.6%," said MetLife President and Chief Executive Officer Michel Khalaf. "Our unyielding focus on execution continues to drive strong momentum across our market-leading businesses."








Page 1 of 24




Third Quarter 2024 Summary
($ in millions, except per share data)
Three Months Ended
September 30,
2024 2023 Change
Premiums, fees and other revenues $ 12,523 $ 13,170 (5)%
Net investment income
5,227 4,825 8%
Net investment gains (losses)
(77) (927)
Net derivative gains (losses)
767 (1,202)
Total revenues
$ 18,440 $ 15,866
Adjusted premiums, fees and other revenues
$ 12,471 $ 13,181 (5)%
Adjusted premiums, fees and other revenues, excluding pension risk transfers (PRT) $ 11,942 $ 11,720 2%
Market risk benefit remeasurement gains (losses) $ (531) $ 796
Net income (loss)
$ 1,275 $ 422 202%
Net income (loss) per share
$ 1.81 $ 0.56 223%
Adjusted earnings
$ 1,375 $ 1,488 (8)%
Adjusted earnings per share
$ 1.95 $ 1.97 (1)%
Adjusted earnings, excluding total notable items
$ 1,359 $ 1,474 (8)%
Adjusted earnings, excluding total notable items per share
$ 1.93 $ 1.95 (1)%
Book value per share
$ 39.02 $ 29.34 33%
Book value per share, excluding AOCI other than FCTA
$ 54.72 $ 53.00 3%
Expense ratio
19.9  % 18.6  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT
11.7  % 12.3  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT 20.7  % 20.6  %
ROE
20.2  % 7.0  %
Adjusted ROE, excluding AOCI other than FCTA
14.6  % 14.9  %
Adjusted ROE, excluding total notable items (excludes AOCI other than FCTA)
14.4  % 14.7  %
Information regarding the non-GAAP and other financial measures included in this news release and reconciliation of the non-GAAP financial measures to GAAP measures are in “Non-GAAP and Other Financial Disclosures” below and in the tables that accompany this news release.
Supplemental slides for the third quarter of 2024, titled “3Q24 Supplemental Slides” are available on the MetLife Investor Relations website at https://investor.metlife.com and in the Form 8-K furnished by MetLife to the U.S. Securities and Exchange Commission in connection with this earnings release. Supplemental information about MetLife's diversified global investment portfolio is contained in the "3Q24 - General Account Assets Under Management Fact Sheet," available on the above-mentioned website.

Page 2 of 24



Total Company Discussion
MetLife reported third quarter 2024 premiums, fees and other revenues of $12.5 billion, down 5 percent compared to the third quarter of 2023. Adjusted premiums, fees and other revenues were also $12.5 billion, down 5 percent on a reported basis and down 4 percent on a constant currency basis from the prior-year period.
Net investment income was $5.2 billion, up 8 percent from the third quarter of 2023, primarily due to higher interest rates and increases in the estimated fair value of certain securities that do not qualify as separate accounts under GAAP. Adjusted net investment income was $5.1 billion, up 2 percent, primarily due to higher interest rates and asset growth.
Net investment losses were $77 million, or $61 million after tax during the quarter, reflecting normal trading activity and a stable credit environment. Net derivative gains amounted to $767 million, or $606 million after tax during the quarter, driven by the strengthening of the yen versus the U.S. dollar and the decline in interest rates in the third quarter, partially offset by market risk benefit remeasurement losses.
Net income was $1.3 billion, compared to net income of $422 million in the third quarter of 2023. The increase in net income was primarily driven by net derivative gains partially offset by market risk benefit remeasurement losses. On a per-share basis, net income was $1.81, compared to net income of $0.56 in the prior-year period.
MetLife reported adjusted earnings of $1.4 billion, down 8 percent on a reported basis, and down 6 percent on a constant currency basis, from the third quarter of 2023. On a per-share basis, adjusted earnings were $1.95, down 1 percent from the prior-year period.

Annual Actuarial Assumption Review and Other Insurance Adjustments
In the third quarter of 2024, MetLife performed its annual global actuarial assumption review. The actuarial assumption review and other insurance adjustments during the quarter positively impacted net income by $10 million and adjusted earnings by $16 million.
Adjusted Earnings by Segment Summary
Three Months Ended
September 30, 2024
Segment Change from
prior-year period (on a reported basis)
Change from
prior-year period
(on a constant
currency basis)
Group Benefits (27)%
Retirement and Income Solutions (RIS) —%
Asia 11% 13%
Latin America 11% 23%
Europe, the Middle East and Africa (EMEA)
(20)% (20)%
MetLife Holdings (13)%

Business Discussions
All comparisons of the results for the third quarter of 2024 in the business discussions that follow are with the third quarter of 2023, unless otherwise noted.
Page 3 of 24



GROUP BENEFITS
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change
Adjusted earnings
$373 $510 (27)%
Notable item(s) $(58) $27
Adjusted earnings ex. notables $431 $483 (11)%
Adjusted premiums, fees and other revenues
$6,146 $5,866 5%

•Adjusted earnings were $373 million, down 27 percent, primarily driven by the impact of a liability refinement included in the annual actuarial assumption review and other insurance adjustments, and less favorable non-medical health underwriting.
•Excluding notable items, adjusted earnings were $431 million, down 11 percent.
•Adjusted premiums, fees and other revenues were $6.1 billion, up 5 percent, primarily driven by strong growth in national accounts.
•Sales were up 9 percent year-to-date, primarily driven by strong growth in national accounts.

RIS
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change
Adjusted earnings
$472 $470 —%
Notable item(s) $104 $61  
Adjusted earnings ex. notables $368 $409 (10)%
Adjusted premiums, fees and other revenues
$1,579 $2,478 (36)%
Adjusted premiums, fees and other revenues, excluding PRT
$1,050 $1,017 3%

•Adjusted earnings were $472 million, essentially flat, driven by the impact of the annual actuarial assumption review and other insurance adjustments, offset by lower recurring interest margins.
•Excluding notable items, adjusted earnings were $368 million, down 10 percent.
•Adjusted premiums, fees and other revenues were $1.6 billion, compared to $2.5 billion in the prior-year period.
•Excluding pension risk transfers, adjusted premiums, fees and other revenues were $1.1 billion, up 3 percent, driven by strong sales in UK longevity reinsurance.
•Sales were up 42 percent year-to-date, driven by most products, including pension risk transfer deals.
Page 4 of 24



ASIA
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change Constant
currency
change
Adjusted earnings $306 $275 11% 13%
Notable item(s) $(41) $(94)
Adjusted earnings ex. notables $347 $369 (6)% (5)%
Adjusted premiums, fees and other revenues
$1,710 $1,743 (2)% —%
Asia general account assets under management (at amortized cost) $135,107 $124,684 8% 6%

•Adjusted earnings were $306 million, up 11 percent on a reported basis, and up 13 percent on a constant currency basis, driven by the impact of the annual actuarial assumption review and other insurance adjustments and favorable underwriting, partially offset by lower investment margins.
•Excluding notable items, adjusted earnings were $347 million, down 6 percent.
•Adjusted premiums, fees and other revenues were $1.7 billion, down 2 percent on a reported basis, and essentially flat on a constant currency basis.
•Asia general account assets under management (at amortized cost) were $135.1 billion, up 8 percent on a reported basis and up 6 percent on a constant currency basis.
•Sales were $590 million, down 1 percent on a constant currency basis, driven by lower sales in Japan, offset by growth in India and China.

LATIN AMERICA
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change Constant
currency
change
Adjusted earnings $221 $199 11% 23%
Notable item(s) $4 $0
Adjusted earnings ex. notables $217 $199 9% 21%
Adjusted premiums, fees and other revenues
$1,496 $1,484 1% 11%

•Adjusted earnings were $221 million, up 11 percent on a reported basis, and up 23 percent on a constant currency basis, driven by higher Chilean encaje returns and volume growth in our key markets.
•Excluding notable items, adjusted earnings were $217 million, up 9 percent.
•Adjusted premiums, fees and other revenues were $1.5 billion, up 1 percent on a reported basis, and up 11 percent on a constant currency basis, driven by strong sales and solid persistency across the region.
•Sales were $383 million, up 12 percent from the prior-year period on a constant currency basis, with all key markets contributing across the region.
Page 5 of 24



EMEA
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change Constant
currency
change
Adjusted earnings
$70 $88 (20)% (20)%
Notable item(s)
$(5) $18
Adjusted earnings ex. notables $75 $70 7% 9%
Adjusted premiums, fees and other revenues
$655 $588 11% 14%

•Adjusted earnings were $70 million, down 20 percent on both a reported basis and a constant currency basis, due to the impact of the annual actuarial assumption review and other insurance adjustments, partially offset by volume growth across the region.
•Excluding notable items, adjusted earnings were $75 million, up 7 percent.
•Adjusted premiums, fees and other revenues were $655 million, up 11 percent on a reported basis and up 14 percent on a constant currency basis due to strong sales across the region.
•Sales were $249 million, up 32 percent on a constant currency basis, with strong growth in Turkey and Egypt.

METLIFE HOLDINGS
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change
Adjusted earnings
$182 $208 (13)%
Notable item(s)
$12 $2
Adjusted earnings ex. notables $170 $206 (17)%
Adjusted premiums, fees and other revenues
$793 $910 (13)%

•Adjusted earnings were $182 million, down 13 percent, primarily as a result of the reinsurance transaction completed in 2023.
•Excluding notable items, adjusted earnings were $170 million, down 17 percent.
•Adjusted premiums, fees and other revenues were $793 million, down 13 percent.

CORPORATE & OTHER
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change
Adjusted earnings $(249) $(262)

•Adjusted loss of $249 million, compared to an adjusted loss of $262 million in the prior-year period.
Page 6 of 24



INVESTMENTS
($ in millions) Three Months Ended
September 30, 2024
Three Months Ended
September 30, 2023
Change
Adjusted net investment income
$5,143 $5,056 2%

•Adjusted net investment income was $5.1 billion, up 2 percent. Recurring investment income was $5.0 billion, compared with $4.9 billion in the prior-year period, driven by higher interest rates and asset growth. Variable investment income was $162 million, compared to $179 million in the prior-year period, driven by lower private equity returns.

THIRD QUARTER 2024 NOTABLE ITEMS
($ in millions)
Adjusted Earnings
Three Months Ended September 30, 2024
Notable Items Group Benefits RIS Asia Latin
America
EMEA MetLife
Holdings
Corporate
&
Other
Total
Actuarial assumption review and other insurance adjustments $(58) $104 $(41) $4 $(5) $12 $0 $16
Total notable items $(58) $104 $(41) $4 $(5) $12 $0 $16

###


Contacts:     For Media:     Dave Franecki (973) 264-7465, Dave.Franecki@metlife.com    
For Investors:      John Hall (212) 578-7888, John.A.Hall@metlife.com

About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.
Conference Call
MetLife will hold its third quarter 2024 earnings conference call on Thursday, October 31, 2024, from 9-10 a.m. (ET). The conference call will be available live via the internet. To listen to the conference call via the internet, click the following link to register (https://registrations.events/direct/Q4I79508686).

The conference call will be available for replay via telephone and the internet beginning at 11:00 a.m. (ET) on Thursday, October 31, 2024, until Thursday, November 7, 2024, at 11:59 p.m. (ET). To listen to a replay of the conference call via telephone, dial 800-770-2030 (U.S.) or 647-362-9199 (outside the U.S.). The Conference ID for the replay is 79508. To access the replay of the conference call via the internet, visit the MetLife Investor Relations webpage (https://investor.metlife.com).
Page 7 of 24









Non-GAAP and Other Financial Disclosures
Any references in this news release (except in this section and the tables that accompany this release) to: should be read as, respectively:
(i) net income (loss); (i)  net income (loss) available to MetLife, Inc.’s common shareholders;
(ii) net income (loss) per share; (ii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(iii) adjusted earnings; (iii) adjusted earnings available to common shareholders;
(iv) adjusted earnings per share; (iv) adjusted earnings available to common shareholders per diluted common share;
(v) book value per share; (v) book value per common share;
(vi) book value per share, excluding AOCI other than FCTA; (vi) book value per common share, excluding AOCI other than FCTA;
(vii) return on equity; and (vii) return on MetLife, Inc.’s common stockholders’ equity; and
(viii) adjusted return on equity, excluding AOCI other than FCTA. (viii) adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA.
In this news release, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). MetLife believes that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of the business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.
The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
Non-GAAP financial measures: Comparable GAAP financial measures:
(i) total adjusted revenues; (i) total revenues;
(ii) total adjusted expenses; (ii) total expenses;
(iii) adjusted premiums, fees and other revenues; (iii) premiums, fees and other revenues;
(iv) adjusted premiums, fees and other revenues, excluding PRT; (iv) premiums, fees and other revenues;
(v) adjusted net investment income; (v) net investment income;
(vi) adjusted capitalization of deferred policy acquisition costs (DAC); (vi) capitalization of DAC;
Page 8 of 24



(vii) adjusted earnings available to common shareholders; (vii) net income (loss) available to MetLife, Inc.’s common shareholders;
(viii) adjusted earnings available to common shareholders, excluding total notable items; (viii) net income (loss) available to MetLife, Inc.’s common shareholders;
(ix) adjusted earnings available to common shareholders per diluted common share; (ix) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(x) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share; (x) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(xi) adjusted return on equity; (xi) return on equity;
(xii) adjusted return on equity, excluding AOCI other than FCTA; (xii) return on equity;
(xiii) adjusted return on equity, excluding total notable items (excludes AOCI other than FCTA); (xiii) return on equity;
(xiv) investment portfolio gains (losses); (xiv) net investment gains (losses);
(xv) derivative gains (losses); (xv) net derivative gains (losses);
(xvi) total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA; (xvi) total MetLife, Inc.’s stockholders’ equity;
(xvii) total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA); (xvii) total MetLife, Inc.’s stockholders’ equity;
(xviii) book value per common share, excluding AOCI other than FCTA; (xviii) book value per common share;
(xix) free cash flow of all holding companies; (xix) MetLife, Inc. (parent company only) net cash provided by (used in) operating activities;
(xx) adjusted other expenses; (xx) other expenses;
(xxi) adjusted other expenses, net of adjusted capitalization of DAC; (xxi) other expenses, net of capitalization of DAC;
(xxii) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses; (xxii) other expenses, net of capitalization of DAC;
(xxiii) adjusted expense ratio; (xxiii) expense ratio;
(xxiv) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT; (xxiv) expense ratio;
(xxv) direct expenses; (xxv) other expenses;
(xxvi) direct expenses, excluding total notable items related to direct expenses; (xxvi) other expenses;
(xxvii) direct expense ratio; and (xxvii) expense ratio; and
(xxviii) direct expense ratio, excluding total notable items related to direct expenses and PRT. (xxviii) expense ratio.
Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the current period and applied to the comparable prior period (“constant currency basis”).
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings news release and in this period’s quarterly financial supplement, which is available at www.metlife.com.
Page 9 of 24



MetLife’s definitions of non-GAAP and other financial measures discussed in this news release may differ from those used by other companies:
Adjusted earnings and related measures
•adjusted earnings;
•adjusted earnings available to common shareholders;
•adjusted earnings available to common shareholders on a constant currency basis;
•adjusted earnings available to common shareholders, excluding total notable items;
•adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis;
•adjusted earnings available to common shareholders per diluted common share;
•adjusted earnings available to common shareholders on a constant currency basis per diluted common share;
•adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and
•adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis per diluted common share.
These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results.
Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.
Adjusted revenues and adjusted expenses
These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.
Market volatility can have a significant impact on MetLife’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.
Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:
•Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments").
•Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance.
Page 10 of 24



•Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
•Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance.
Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.
Other adjustments are made to the line items indicated in calculating adjusted earnings:
•Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs").
•Other revenues include fee revenue on synthetic guaranteed interest contracts ("GICs") accounted for as freestanding derivatives.
•Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
•Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.
The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.
In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium, which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders.
Investment portfolio gains (losses) and derivative gains (losses)
These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).
Return on equity and related measures
•Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment components of AOCI, net of income tax.
Page 11 of 24



•Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, and total notable items, net of income tax.
•Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.’s average common stockholders’ equity.
•Adjusted return on MetLife, Inc.'s common stockholders' equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders' equity.
•Adjusted return on MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders' equity, excluding AOCI other than FCTA.
•Adjusted return on MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA).
The above measures represent a level of equity consistent with the view that, in the ordinary course of business, MetLife does not plan to sell most investments for the sole purpose of realizing gains or losses.
Expense ratio, direct expense ratio, adjusted expense ratio and related measures
•Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.
•Direct expense ratio: adjusted direct expenses, divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third-party staffing costs, and general and administrative expenses.
•Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
•Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.
•Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Asia General account (GA) assets under management (GA AUM) and related measures
Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio. Asia GA AUM is stated at estimated fair value and is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties, assets subject to reinsurance arrangements with third-party reinsurers, and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties ("net mortgage loans") (including commercial ("net commercial mortgage loans"), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.
Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on net mortgage loans (including net commercial mortgage loans, net agricultural mortgage loans and residential mortgage loans) and real estate and real estate joint ventures.
Page 12 of 24



Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.
Statistical sales information:
•Group Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products.
•RIS: calculated using 10% of single premium contracts, on and off-balance sheet deposits, and the contract value for new UK longevity reinsurance contracts, and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance.
•Latin America, Asia and EMEA: calculated using 10% of single premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group).
Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.
The following additional information is relevant to an understanding of MetLife’s performance results and outlook:
•Volume growth, as discussed in the context of business growth, is the period over period percentage change in adjusted earnings available to common shareholders attributable to adjusted premiums, fees and other revenues and assets under management levels, applying a model in which certain margins and factors are held constant. The most significant of such items are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates.
•Holding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block.
•MetLife uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. MetLife defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders.
•Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders.
•We refer to observable forward yield curves as of a particular date in connection with making our estimates for future results. The observable forward yield curves at a given time are based on implied future interest rates along a range of interest rate durations. This includes the 10-year U.S. Treasury rate which we use as a benchmark rate to describe longer-term interest rates used in our estimates for future results.

Page 13 of 24



Forward-Looking Statements
This news release may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” "are confident," “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would,” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, future sales efforts, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.
Many factors determine the results of MetLife, Inc., its subsidiaries and affiliates, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. MetLife, Inc. does not guarantee any future performance. Our results could differ materially from those MetLife, Inc. expresses or implies in forward-looking statements. The risks, uncertainties and other factors identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:
(1)economic condition difficulties, including risks relating to interest rates, credit spreads, declining equity or debt markets, real estate, obligors and counterparties, government default, currency exchange rates, derivatives, climate change, public health and terrorism and security;
(2)global capital and credit market adversity;
(3)credit facility inaccessibility;
(4)financial strength or credit ratings downgrades;
(5)unavailability, unaffordability, or inadequate reinsurance, including reinsurance risks that arise from reinsurers' credit risk, and the potential shortfall or failure of risk mitigants to protect against such risks;
(6)statutory life insurance reserve financing costs or limited market capacity;
(7)legal, regulatory, and supervisory and enforcement policy changes;
(8)changes in tax rates, tax laws or interpretations;
(9)litigation and regulatory investigations;
(10)unsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;
(11)MetLife, Inc.’s inability to pay dividends and repurchase common stock;
(12)MetLife, Inc.’s subsidiaries’ inability to pay dividends to MetLife, Inc.;
(13)investment defaults, downgrades, or volatility;
(14)investment sales or lending difficulties;
(15)collateral or derivative-related payments;
(16)investment valuations, allowances, or impairments changes;
(17)claims or other results that differ from our estimates, assumptions, or models;
(18)global political, legal, or operational risks;
(19)business competition;
(20)technological changes;
(21)catastrophes;
(22)climate changes or responses to it;
(23)deficiencies in our closed block;
(24)goodwill or other asset impairment, or deferred income tax asset allowance;
(25)impairment of VOBA, value of distribution agreements acquired or value of customer relationships acquired;
(26)product guarantee volatility, costs, and counterparty risks;
(27)risk management failures;
(28)insufficient protection from operational risks;
Page 14 of 24



(29)failure to protect confidentiality and integrity of data or other cybersecurity or disaster recovery failures;
(30)accounting standards changes;
(31)excessive risk-taking;
(32)marketing and distribution difficulties;
(33)pension and other postretirement benefit assumption changes;
(34)inability to protect our intellectual property or avoid infringement claims;
(35)acquisition, integration, growth, disposition, or reorganization difficulties;
(36)Brighthouse Financial, Inc. separation risks;
(37)MetLife, Inc.’s Board of Directors influence over the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; and
(38)legal- and corporate governance-related effects on business combinations.
MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.

Page 15 of 24



MetLife, Inc.
GAAP Interim Condensed Consolidated Statements of Operations
(In millions)
For the Three Months Ended
September 30,
2024 2023
Revenues
Premiums $ 10,647  $ 11,230 
Universal life and investment-type product policy fees 1,228  1,334 
Net investment income 5,227  4,825 
Other revenues 648  606 
Net investment gains (losses) (77) (927)
Net derivative gains (losses) 767  (1,202)
Total revenues 18,440  15,866 
Expenses
Policyholder benefits and claims 10,597  11,130 
Policyholder liability remeasurement (gains) losses (132) (17)
Market risk benefit remeasurement (gains) losses 531  (796)
Interest credited to policyholder account balances 2,037  1,658 
Policyholder dividends 150  153 
Amortization of DAC and VOBA 516  499 
Amortization of negative VOBA (7) (7)
Interest expense on debt 257  265 
Other expenses, net of capitalization of DAC 2,497  2,447 
Total expenses 16,446  15,332 
Income (loss) before provision for income tax 1,994  534 
Provision for income tax expense (benefit) 653  39 
Net income (loss) 1,341  495 
Less: Net income (loss) attributable to noncontrolling interests (1)
Net income (loss) attributable to MetLife, Inc. 1,342  489 
Less: Preferred stock dividends 67  67 
Net income (loss) available to MetLife, Inc.'s common shareholders $ 1,275  $ 422 
See footnotes on last page.
Page 16 of 24



MetLife, Inc.
(In millions, except per share data)
For the Three Months Ended
September 30,
2024 2023
Reconciliation to Adjusted Earnings Available to Common Shareholders Earnings Per
Weighted Average
Common Share Diluted (1)
Earnings Per
Weighted Average
Common Share Diluted (1)
Net income (loss) available to MetLife, Inc.'s common shareholders $ 1,275  $ 1.81  $ 422  $ 0.56 
Adjustments from net income (loss) available to common shareholders to adjusted earnings available to common shareholders:
Less: Net investment gains (losses) (77) (0.11) (927) (1.23)
Net derivative gains (losses) 767  1.09  (1,202) (1.59)
Market risk benefit remeasurement gains (losses) (531) (0.75) 796  1.05 
Premiums 16  0.02  —  — 
Universal life and investment-type product policy fees —  —  —  — 
Net investment income 84  0.12  (231) (0.31)
Other revenues 36  0.05  (11) (0.01)
Policyholder benefits and claims and policyholder dividends 50  0.08  69  0.10 
Policyholder liability remeasurement (gains) losses —  —  —  — 
Interest credited to policyholder account balances (222) (0.32) 47  0.06 
Capitalization of DAC —  —  —  — 
Amortization of DAC and VOBA —  —  —  — 
Amortization of negative VOBA —  —  —  — 
Interest expense on debt —  —  —  — 
Other expenses (29) (0.04) (30) (0.04)
Goodwill impairment —  —  —  — 
Provision for income tax (expense) benefit (195) (0.28) 429  0.57 
Add: Net income (loss) attributable to noncontrolling interests (1) —  0.01 
Preferred stock redemption premium —  —  —  — 
Adjusted earnings available to common shareholders 1,375  1.95  1,488  1.97 
Less: Total notable items 16  0.02  14  0.02 
Adjusted earnings available to common shareholders, excluding total notable items $ 1,359  $ 1.93  $ 1,474  $ 1.95 
Adjusted earnings available to common shareholders on a constant currency basis $ 1,375  $ 1.95  $ 1,463  $ 1.94 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis $ 1,359  $ 1.93  $ 1,449  $ 1.92 
Weighted average common shares outstanding - diluted 703.7  755.5 
See footnotes on last page.
Page 17 of 24



MetLife, Inc.
(In millions)
 For the Three Months Ended
September 30,
2024 2023
Premiums, Fees and Other Revenues
Premiums, fees and other revenues $ 12,523  $ 13,170 
Less: Adjustments to premiums, fees and other revenues:
Asymmetrical and non-economic accounting 50  — 
Other adjustments (14) (11)
Divested businesses 16  — 
Adjusted premiums, fees and other revenues $ 12,471  $ 13,181 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 12,471  $ 12,992 
Less: PRT 529  1,461 
Adjusted premiums, fees and other revenues, excluding PRT, on a constant currency basis $ 11,942  $ 11,531 
Net Investment Income
Net investment income $ 5,227  $ 4,825 
Less: Adjustments to net investment income
Investment hedge adjustments (129) (232)
Unit-linked contract income 147 
Other adjustments 66  (3)
Divested businesses —  — 
Adjusted net investment income $ 5,143  $ 5,056 
Revenues and Expenses
Total revenues $ 18,440  $ 15,866 
Less: Adjustments to total revenues:
Net investment gains (losses) (77) (927)
Net derivative gains (losses) 767  (1,202)
Investment hedge adjustments (129) (232)
Asymmetrical and non-economic accounting 50  — 
Unit-linked contract income 147 
Other adjustments 52  (14)
Divested businesses 16  — 
Total adjusted revenues $ 17,614  $ 18,237 
Total expenses $ 16,446  $ 15,332 
Less: Adjustments to total expenses:
Market risk benefit remeasurement (gains) losses 531  (796)
Goodwill impairment —  — 
Asymmetrical and non-economic accounting 72  (49)
Market volatility (52) (64)
Unit-linked contract costs 143  (3)
Other adjustments 12  21 
Divested businesses 26 
Total adjusted expenses $ 15,714  $ 16,214 
See footnotes on last page.
Page 18 of 24



MetLife, Inc.
(In millions, except per share and ratio data)
For the Three Months Ended
September 30,
2024 2023
Expense Detail and Ratios
Reconciliation of Capitalization of DAC to Adjusted Capitalization of DAC
Capitalization of DAC $ (691) $ (742)
Less: Divested businesses —  — 
Adjusted capitalization of DAC $ (691) $ (742)
Reconciliation of Other Expenses to Adjusted Other Expenses
Other expenses $ 3,188  $ 3,189 
Less: Other adjustments 12  21 
Less: Divested businesses 17 
Adjusted other expenses $ 3,159  $ 3,159 
Other Detail and Ratios
Other expenses, net of capitalization of DAC $ 2,497  $ 2,447 
Premiums, fees and other revenues $ 12,523  $ 13,170 
Expense ratio 19.9  % 18.6  %
Direct expenses $ 1,392  $ 1,447 
Less: Total notable items related to direct expenses —  — 
Direct expenses, excluding total notable items related to direct expenses $ 1,392  $ 1,447 
Adjusted other expenses $ 3,159  $ 3,159 
Adjusted capitalization of DAC (691) (742)
Adjusted other expenses, net of adjusted capitalization of DAC 2,468  2,417 
Less: Total notable items related to adjusted other expenses —  — 
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses $ 2,468  $ 2,417 
Adjusted premiums, fees and other revenues $ 12,471  $ 13,181 
Less: PRT 529  1,461 
Adjusted premiums, fees and other revenues, excluding PRT $ 11,942  $ 11,720 
Direct expense ratio 11.2  % 11.0  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT 11.7  % 12.3  %
Adjusted expense ratio 19.8  % 18.3  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT 20.7  % 20.6  %
See footnotes on last page.
Page 19 of 24



MetLife, Inc.
(In millions, except per share data)
September 30,
Equity Details 2024 2023
Total MetLife, Inc.'s stockholders' equity $ 30,885  $ 25,658 
Less: Preferred stock 3,818  3,818 
MetLife, Inc.'s common stockholders' equity 27,067  21,840 
Less: Net unrealized investment gains (losses), net of income tax (11,531) (26,548)
Future policy benefits discount rate remeasurement gain (losses), net of income tax 2,004  10,245 
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax (4)
  Defined benefit plans adjustment, net of income tax (1,371) (1,308)
Total MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA 37,961  39,455 
Less: Accumulated year-to-date total notable items 16  14 
Total MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) $ 37,945  $ 39,441 
September 30,
Book Value (2) 2024 2023
Book value per common share $ 39.02  $ 29.34 
Less: Net unrealized investment gains (losses), net of income tax (16.62) (35.66)
Future policy benefits discount rate remeasurement gain (losses), net of income tax 2.89  13.77 
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax 0.01  (0.01)
   Defined benefit plans adjustment, net of income tax (1.98) (1.76)
Book value per common share, excluding AOCI other than FCTA $ 54.72  $ 53.00 
Common shares outstanding, end of period (3) 693.7  744.4 

For the Three Months Ended
September 30, (4)
Return on Equity 2024 2023
Return on MetLife, Inc.'s:
Common stockholders' equity 20.2  % 7.0  %
Adjusted return on MetLife, Inc.'s:
Common stockholders' equity 21.8  % 24.7  %
Common stockholders' equity, excluding AOCI other than FCTA 14.6  % 14.9  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) 14.4  % 14.7  %
For the Three Months Ended
September 30,
Average Common Stockholders' Equity 2024 2023
Average common stockholders' equity $ 25,251  $ 24,142 
Average common stockholders' equity, excluding AOCI other than FCTA $ 37,673  $ 40,001 
Average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) $ 37,665  $ 39,994 
See footnotes on last page.
Page 20 of 24



MetLife, Inc.
Adjusted Earnings Available to Common Shareholders
(In millions)
For the Three Months Ended
September 30,
2024 2023
Group Benefits (5):
Adjusted earnings available to common shareholders $ 373  $ 510 
Less: Total notable items (58) 27 
Adjusted earnings available to common shareholders, excluding total notable items $ 431  $ 483 
Adjusted premiums, fees and other revenues $ 6,146  $ 5,866 
Retirement & Income Solutions (5):
Adjusted earnings available to common shareholders $ 472  $ 470 
Less: Total notable items 104  61 
Adjusted earnings available to common shareholders, excluding total notable items $ 368  $ 409 
Adjusted premiums, fees and other revenues $ 1,579  $ 2,478 
Less: PRT 529  1,461 
Adjusted premiums, fees and other revenues, excluding PRT $ 1,050  $ 1,017 
Asia:
Adjusted earnings available to common shareholders $ 306  $ 275 
Less: Total notable items (41) (94)
Adjusted earnings available to common shareholders, excluding total notable items $ 347  $ 369 
Adjusted earnings available to common shareholders on a constant currency basis $ 306  $ 271 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis $ 347  $ 365 
Adjusted premiums, fees and other revenues $ 1,710  $ 1,743 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,710  $ 1,704 
Latin America:
Adjusted earnings available to common shareholders $ 221  $ 199 
Less: Total notable items — 
Adjusted earnings available to common shareholders, excluding total notable items $ 217  $ 199 
Adjusted earnings available to common shareholders on a constant currency basis $ 221  $ 179 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis $ 217  $ 179 
Adjusted premiums, fees and other revenues $ 1,496  $ 1,484 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,496  $ 1,349 
See footnotes on last page.
Page 21 of 24



MetLife, Inc.
Adjusted Earnings Available to Common Shareholders (Continued)
(In millions)
For the Three Months Ended
September 30,
2024 2023
EMEA:
Adjusted earnings available to common shareholders $ 70  $ 88 
Less: Total notable items (5) 18 
Adjusted earnings available to common shareholders, excluding total notable items $ 75  $ 70 
Adjusted earnings available to common shareholders on a constant currency basis $ 70  $ 87 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis $ 75  $ 69 
Adjusted premiums, fees and other revenues $ 655  $ 588 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 655  $ 573 
MetLife Holdings (5):
Adjusted earnings available to common shareholders $ 182  $ 208 
Less: Total notable items 12 
Adjusted earnings available to common shareholders, excluding total notable items $ 170  $ 206 
Adjusted premiums, fees and other revenues $ 793  $ 910 
Corporate & Other (5):
Adjusted earnings available to common shareholders $ (249) $ (262)
Less: Total notable items —  — 
Adjusted earnings available to common shareholders, excluding total notable items $ (249) $ (262)
Adjusted premiums, fees and other revenues $ 92  $ 112 
See footnotes on last page.









Page 22 of 24



MetLife, Inc.
For the Three Months Ended
September 30,
2024 2023
Variable investment income (post-tax, in millions) (6)
Group Benefits $ $
RIS 50  35 
Asia 44  37 
Latin America
EMEA —  — 
MetLife Holdings 29  35 
Corporate & Other (5) 28 
Total variable investment income $ 128  $ 141 
Segments: Group Benefits, RIS, Asia, Latin America and EMEA (7)
Capital Deployed Value of New Business Internal Rate of Return Payback (Years)
Value of new business ($ in billions)
2023 $ 3.6  $ 2.6  19  %
2022 $ 3.7  $ 2.3  17  %
2021 $ 2.8  $ 1.9  17  %
2020 $ 3.2  $ 1.9  17  %
2019 $ 3.8  $ 1.8  15  %
See footnotes on last page.

Page 23 of 24



MetLife, Inc.
September 30, 2024
Cash & Capital (8), (9) (in billions)
Holding Companies Cash & Liquid Assets
$ 4.5 
Footnotes
(1)
Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share is calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.
(2) Book values exclude $3,818 million of equity related to preferred stock at both September 30, 2024 and 2023.
(3) There were share repurchases of approximately $0.8 billion for the three months September 30, 2024. There were share repurchases of approximately $130 million in October 2024.
(4) Annualized using quarter-to-date results.
(5) Results on a constant currency basis are not included as constant currency impact is not significant.
(6)
Assumes a 21% tax rate.
(7) Excludes MetLife Holdings; Value of New Business is the present value of future profits net of the cost of capital and time value of guarantees from new sales.
(8)
The total U.S. statutory adjusted capital is expected to be approximately $17.6 billion at September 30, 2024, down 2% from June 30, 2024. This balance includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company.
(9)
The expected Japan solvency margin ratio as of September 30, 2024 is approximately 745%.
Page 24 of 24

EX-99.2 3 ex992qfsq324.htm EX-99.2 Document
Exhibit 99.2




 image0a45a.jpg
Third Quarter
Financial Supplement
September 30, 2024
3


METLIFE
TABLE OF CONTENTS
 
 
 
 
 
1

METLIFE
As used in this QFS, “MetLife," “we” and “our” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. In this QFS, MetLife presents certain measures of its performance that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of its business. See Appendix for definitions of non-GAAP financial measures and other financial disclosures.
GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Revenues
Premiums $ 11,230  $ 11,786  $ 10,053  $ 11,628  $ 10,647  $ 32,497  $ 32,328 
Universal life and investment-type product policy fees 1,334  1,241  1,248  1,281  1,228  3,911  3,757 
Net investment income 4,825  5,366  5,436  5,205  5,227  14,542  15,868 
Other revenues 606  660  674  638  648  1,866  1,960 
Net investment gains (losses) (927) (174) (375) (421) (77) (2,650) (873)
Net derivative gains (losses) (1,202) 149  (979) (508) 767  (2,289) (720)
Total revenues 15,866  19,028  16,057  17,823  18,440  47,877  52,320 
Expenses
Policyholder benefits and claims 11,130  11,779  10,074  11,485  10,597  32,811  32,156 
Policyholder liability remeasurement (gains) losses (17) (3) (22) (10) (132) (42) (164)
Market risk benefit remeasurement (gains) losses (796) 431  (694) (182) 531  (1,425) (345)
Interest credited to policyholder account balances 1,658  2,405  2,290  2,000  2,037  5,455  6,327 
Policyholder dividends 153  159  147  148  150  463  445 
Amortization of DAC and VOBA 499  504  508  499  516  1,448  1,523 
Amortization of negative VOBA (7) (6) (6) (6) (7) (20) (19)
Interest expense on debt 265  269  264  257  257  776  778 
Other expenses, net of capitalization of DAC 2,447  2,549  2,451  2,430  2,497  7,190  7,378 
Total expenses 15,332  18,087  15,012  16,621  16,446  46,656  48,079 
Income (loss) before provision for income tax 534  941  1,045  1,202  1,994  1,221  4,241 
Provision for income tax expense (benefit) 39  327  170  249  653  233  1,072 
Net income (loss) 495  614  875  953  1,341  988  3,169 
Less: Net income (loss) attributable to noncontrolling interests (1) 17  14 
Net income (loss) attributable to MetLife, Inc. 489  607  867  946  1,342  971  3,155 
Less: Preferred stock dividends 67  33  67  34  67  165  168 
Net income (loss) available to MetLife, Inc.'s common shareholders $ 422  $ 574  $ 800  $ 912  $ 1,275  $ 806  $ 2,987 
Premiums, fees and other revenues $ 13,170  $ 13,687  $ 11,975  $ 13,547  $ 12,523  $ 38,274  $ 38,045 
2

METLIFE
CORPORATE OVERVIEW
For the Three Months Ended
Unaudited (In millions, except per share data) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Net income (loss) available to MetLife, Inc.'s common shareholders $ 422  $ 574  $ 800  $ 912  $ 1,275 
Adjustments from net income (loss) available to MetLife, Inc.'s common shareholders to adjusted earnings available to common shareholders:
Less: Net investment gains (losses) (927) (174) (375) (421) (77)
Less: Net derivative gains (losses) (1,202) 149  (979) (508) 767 
Less: Market risk benefit remeasurement gains (losses) 796  (431) 694  182  (531)
Less: Goodwill impairment —  —  —  —  — 
Less: Other adjustments to net income (loss) (1) (156) (330) (126) (232) (65)
Less: Provision for income tax (expense) benefit 429  260  270  (195)
Add: Net income (loss) attributable to noncontrolling interests (1)
Add: Preferred stock redemption premium —  —  —  —  — 
Adjusted earnings available to common shareholders 1,488  1,361  1,334  1,628  1,375 
Less: Total notable items (2) 14  (76) —  —  16 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 1,474  $ 1,437  $ 1,334  $ 1,628  $ 1,359 
Net income (loss) available to MetLife, Inc.'s common shareholders per diluted common share $ 0.56  $ 0.77  $ 1.10  $ 1.28  $ 1.81 
Less: Net investment gains (losses) (1.23) (0.23) (0.51) (0.59) (0.11)
Less: Net derivative gains (losses) (1.59) 0.20  (1.34) (0.71) 1.09 
Less: Market risk benefit remeasurement gains (losses) 1.05  (0.58) 0.95  0.25  (0.75)
Less: Goodwill impairment —  —  —  —  — 
Less: Other adjustments to net income (loss) (0.20) (0.45) (0.18) (0.32) (0.09)
Less: Provision for income tax (expense) benefit 0.57  0.01  0.36  0.38  (0.28)
Add: Net income (loss) attributable to noncontrolling interests 0.01  0.01  0.01  0.01  — 
Add: Preferred stock redemption premium —  —  —  —  — 
Adjusted earnings available to common shareholders per diluted common share 1.97  1.83  1.83  2.28  1.95 
Less: Total notable items per diluted common share (2) 0.02  (0.10) —  —  0.02 
Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share (2), (3) $ 1.95  $ 1.93  $ 1.83  $ 2.28  $ 1.93 
For the Three Months Ended
Unaudited (In millions, except per share data) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Notable items impacting adjusted earnings available to common shareholders (2):
Actuarial assumption review and other insurance adjustments $ 14  $ —  $ —  $ —  $ 16 
Litigation reserves and settlement costs —  (76) —  —  — 
Total notable items  $ 14  $ (76) $ —  $ —  $ 16 
Notable items impacting adjusted earnings available to common shareholders per diluted common share (2):
Actuarial assumption review and other insurance adjustments $ 0.02  $ —  $ —  $ —  $ 0.02 
Litigation reserves and settlement costs —  (0.10) —  —  — 
Total notable items  $ 0.02  $ (0.10) $ —  $ —  $ 0.02 
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Weighted average common shares outstanding - diluted 755.5  743.4  728.4  714.7  703.7 
(1)See Pages A-1 and A-7 for further detail.
(2)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders and adjusted earnings available to common shareholders per diluted common share. The per share data for each notable item is calculated on a standalone basis and may not sum to total notable items. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. See Page A-2 for further detail.
(3)Calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.

3

METLIFE
CORPORATE OVERVIEW (CONTINUED)
Unaudited September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Book value per common share (1) $ 29.34  $ 35.85  $ 34.54  $ 33.30  $ 39.02 
Book value per common share, excluding AOCI other than FCTA (1) $ 53.00  $ 53.75  $ 53.13  $ 53.12  $ 54.72 
For the Three Months Ended
Unaudited September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Return on MetLife, Inc.'s (2):
Common stockholders' equity 7.0  % 9.6  % 12.6  % 15.2  % 20.2  %
Adjusted return on MetLife, Inc.'s (2):
Common stockholders' equity 24.7  % 22.7  % 21.0  % 27.0  % 21.8  %
Common stockholders' equity, excluding AOCI other than FCTA 14.9  % 13.8  % 13.8  % 17.3  % 14.6  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (3) 14.7  % 14.6  % 13.8  % 17.3  % 14.4  %
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Common shares outstanding, beginning of period 757.2  744.4  730.8  715.7  703.8 
Share repurchases (12.9) (13.7) (16.9) (12.0) (10.5)
Newly issued shares 0.1  0.1  1.8  0.1  0.4 
Common shares outstanding, end of period 744.4  730.8  715.7  703.8  693.7 
Weighted average common shares outstanding - basic 751.4  738.6  723.2  710.5  699.3 
Dilutive effect of the exercise or issuance of stock-based awards 4.1  4.8  5.2  4.2  4.4 
Weighted average common shares outstanding - diluted 755.5  743.4  728.4  714.7  703.7 
MetLife Policyholder Trust Shares 119.1  117.6  116.0  114.3  113.1 
(1) Calculated using common shares outstanding, end of period.
(2) Annualized using quarter-to-date results. See Page A-4 for further detail.
(3)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.

4

METLIFE
KEY ADJUSTED EARNINGS STATEMENT LINE ITEMS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Total revenues $ 15,866  $ 19,028  $ 16,057  $ 17,823  $ 18,440  $ 47,877  $ 52,320 
Less: Adjustments to total revenues:
Net investment gains (losses) (927) (174) (375) (421) (77) (2,650) (873)
Net derivative gains (losses) (1,202) 149  (979) (508) 767  (2,289) (720)
Investment hedge adjustments (232) (253) (176) (172) (129) (759) (477)
Asymmetrical and non-economic accounting —  29  39  35  50  —  124 
Unit-linked contract income 580  542  219  147  603  908 
Other adjustments (14) (21) (10) (13) 52  (25) 29 
Divested businesses
—  —  —  —  16  —  16 
Total adjusted revenues $ 18,237  $ 18,718  $ 17,016  $ 18,683  $ 17,614  $ 52,997  $ 53,313 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Net investment income $ 4,825  $ 5,366  $ 5,436  $ 5,205  $ 5,227  $ 14,542  $ 15,868 
Less: Adjustments to net investment income:
Investment hedge adjustments (232) (253) (176) (172) (129) (759) (477)
Unit-linked contract income 580  542  219  147  603  908 
Other adjustments (3) (8) (2) 66  (4) 66 
Divested businesses —  —  —  —  —  —  — 
Adjusted net investment income $ 5,056  $ 5,047  $ 5,068  $ 5,160  $ 5,143  $ 14,702  $ 15,371 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Variable investment income (Included in net investment income above) $ 179  $ 63  $ 260  $ 298  $ 162  $ 356  $ 720 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Premiums, fees and other revenues $ 13,170  $ 13,687  $ 11,975  $ 13,547  $ 12,523  $ 38,274  $ 38,045 
Less: Adjustments to premiums, fees and other revenues:
Asymmetrical and non-economic accounting —  29  39  35  50  —  124 
Other adjustments (11) (13) (12) (11) (14) (21) (37)
Divested businesses
—  —  —  —  16  —  16 
Adjusted premiums, fees and other revenues $ 13,181  $ 13,671  $ 11,948  $ 13,523  $ 12,471  $ 38,295  $ 37,942 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 12,992  $ 13,554  $ 11,838  $ 13,490  $ 12,471 
5

METLIFE
KEY ADJUSTED EARNINGS STATEMENT LINE ITEMS (CONTINUED)
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Total expenses $ 15,332  $ 18,087  $ 15,012  $ 16,621  $ 16,446  $ 46,656  $ 48,079 
Less: Adjustments to total expenses:
Market risk benefit remeasurement (gains) losses (796) 431  (694) (182) 531  (1,425) (345)
Goodwill impairment —  —  —  —  —  —  — 
Asymmetrical and non-economic accounting (49) 129  38  166  72  118  276 
Market volatility (64) (62) (67) (88) (52) (122) (207)
Unit-linked contract costs (3) 582  539  214  143  601  896 
Other adjustments 21  12  48  24 
Divested businesses
26  29  34 
Total adjusted expenses $ 16,214  $ 16,991  $ 15,185  $ 16,502  $ 15,714  $ 47,407  $ 47,401 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Capitalization of DAC $ (742) $ (728) $ (740) $ (683) $ (691) $ (2,189) $ (2,114)
Less: Divested businesses —  —  —  —  —  —  — 
Adjusted capitalization of DAC $ (742) $ (728) $ (740) $ (683) $ (691) $ (2,189) $ (2,114)
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Other expenses $ 3,189  $ 3,277  $ 3,191  $ 3,113  $ 3,188  $ 9,379  $ 9,492 
Less: Adjustments to other expenses:
Other adjustments 21  12  48  24 
Divested businesses 17  29  25 
Adjusted other expenses $ 3,159  $ 3,261  $ 3,180  $ 3,104  $ 3,159  $ 9,302  $ 9,443 
Adjusted other expenses on a constant currency basis $ 3,085  $ 3,215  $ 3,139  $ 3,105  $ 3,159 
6

METLIFE
EXPENSE DETAIL AND RATIOS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions, except ratio data) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Other expenses, net of capitalization of DAC $ 2,447  $ 2,549  $ 2,451  $ 2,430  $ 2,497  $ 7,190  $ 7,378 
Premiums, fees and other revenues $ 13,170  $ 13,687  $ 11,975  $ 13,547  $ 12,523  $ 38,274  $ 38,045 
Expense ratio 18.6  % 18.6  % 20.5  % 17.9  % 19.9  % 18.8  % 19.4  %
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted other expenses by major category
Direct expenses $ 1,447  $ 1,559  $ 1,426  $ 1,397  $ 1,392  $ 4,249  $ 4,215 
Pension, postretirement and postemployment benefit costs 59  69  65  65  65  177  195 
Premium taxes, other taxes, and licenses & fees 162  153  176  171  183  507  530 
Commissions and other variable expenses 1,491  1,480  1,513  1,471  1,519  4,369  4,503 
Adjusted other expenses
3,159  3,261  3,180  3,104  3,159  9,302  9,443 
Adjusted capitalization of DAC (742) (728) (740) (683) (691) (2,189) (2,114)
Adjusted other expenses, net of adjusted capitalization of DAC
$ 2,417  $ 2,533  $ 2,440  $ 2,421  $ 2,468  $ 7,113  $ 7,329 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions, except ratio data) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Employee-related costs $ 913  $ 882  $ 950  $ 900  $ 891  $ 2,737  $ 2,741 
Third-party staffing costs 350  399  342  356  354  1,027  1,052 
General and administrative expenses 184  278  134  141  147  485  422 
Direct expenses 1,447  1,559  1,426  1,397  1,392  4,249  4,215 
Less: Total notable items related to direct expenses (1) —  96  —  —  —  —  — 
Direct expenses, excluding total notable items related to direct expenses (1) $ 1,447  $ 1,463  $ 1,426  $ 1,397  $ 1,392  $ 4,249  $ 4,215 
Adjusted other expenses, net of adjusted capitalization of DAC
$ 2,417  $ 2,533  $ 2,440  $ 2,421  $ 2,468  $ 7,113  $ 7,329 
Less: Total notable items related to adjusted other expenses (1) —  96  —  —  —  —  — 
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (1)
$ 2,417  $ 2,437  $ 2,440  $ 2,421  $ 2,468  $ 7,113  $ 7,329 
Adjusted premiums, fees and other revenues $ 13,181  $ 13,671  $ 11,948  $ 13,523  $ 12,471  $ 38,295  $ 37,942 
Less: PRT 1,461  1,860  (25) 1,752  529  3,464  2,256 
Adjusted premiums, fees and other revenues, excluding PRT $ 11,720  $ 11,811  $ 11,973  $ 11,771  $ 11,942  $ 34,831  $ 35,686 
Direct expense ratio 11.0  % 11.4  % 11.9  % 10.3  % 11.2  % 11.1  % 11.1  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT (1) 12.3  % 12.4  % 11.9  % 11.9  % 11.7  % 12.2  % 11.8  %
Adjusted expense ratio 18.3  % 18.5  % 20.4  % 17.9  % 19.8  % 18.6  % 19.3  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (1) 20.6  % 20.6  % 20.4  % 20.6  % 20.7  % 20.4  % 20.5  %
(1)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.

7

METLIFE
GAAP CONSOLIDATED BALANCE SHEETS
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
ASSETS
Investments:
Fixed maturity securities available-for-sale, at estimated fair value $ 270,982  $ 281,412  $ 278,409  $ 277,736  $ 293,779 
Equity securities, at estimated fair value 742  757  750  754  746 
Contractholder-directed equity securities and fair value option securities, at estimated fair value 9,680  10,331  10,313  10,106  9,289 
Mortgage loans 92,230  92,506  91,458  89,802  90,415 
Policy loans 8,725  8,788  8,800  8,691  8,822 
Real estate and real estate joint ventures 13,133  13,332  12,992  13,517  13,731 
Other limited partnership interests 14,918  14,764  14,301  14,288  14,186 
Short-term investments, principally at estimated fair value 6,497  6,045  4,884  3,804  4,609 
Other invested assets 18,755  18,202  18,097  18,131  19,706 
Total investments 435,662  446,137  440,004  436,829  455,283 
Cash and cash equivalents, principally at estimated fair value 14,912  20,639  19,840  20,786  21,765 
Accrued investment income 3,704  3,589  3,636  3,657  3,722 
Premiums, reinsurance and other receivables 19,002  28,971  29,986  31,820  31,443 
Market risk benefits, at estimated fair value 334  286  351  356  310 
Deferred policy acquisition costs and value of business acquired 19,737  20,151  19,842  19,568  20,401 
Current income tax recoverable —  190  —  348  304 
Deferred income tax assets 3,174  2,612  2,751  2,681  2,469 
Goodwill 9,109  9,236  9,037  8,950  9,155 
Other assets 10,862  11,139  11,126  11,043  11,315 
Separate account assets 135,624  144,634  141,003  139,707  148,809 
Total assets $ 652,120  $ 687,584  $ 677,576  $ 675,745  $ 704,976 
LIABILITIES AND EQUITY
Liabilities
Future policy benefits $ 181,755  $ 196,406  $ 191,013  $ 190,993  $ 201,340 
Policyholder account balances 213,933  219,269  219,168  219,543  224,609 
Market risk benefits, at estimated fair value 2,738  3,179  2,696  2,618  3,117 
Other policy-related balances 19,665  19,736  20,219  19,379  19,932 
Policyholder dividends payable 381  386  357  365  381 
Payables for collateral under securities loaned and other transactions 17,797  17,524  17,470  17,719  17,132 
Short-term debt 161  119  127  390  404 
Long-term debt 15,475  15,548  15,972  14,809  15,278 
Collateral financing arrangement 651  637  590  555  529 
Junior subordinated debt securities 3,160  3,161  3,162  3,163  3,163 
Current income tax payable 59  —  10  —  — 
Deferred income tax liability 128  927  835  216  956 
Other liabilities 34,698  35,805  36,158  38,748  38,162 
Separate account liabilities 135,624  144,634  141,003  139,707  148,809 
Total liabilities 626,225  657,331  648,780  648,205  673,812 
Equity
Preferred stock, at par value —  —  —  —  — 
Common stock, at par value 12  12  12  12  12 
Additional paid-in capital 33,666  33,690  33,718  33,740  33,766 
Retained earnings 39,958  40,146  40,350  40,873  41,765 
Treasury stock, at cost (23,724) (24,591) (25,774) (26,637) (27,418)
Accumulated other comprehensive income (loss) (24,254) (19,242) (19,771) (20,736) (17,240)
Total MetLife, Inc.'s stockholders' equity 25,658  30,015  28,535  27,252  30,885 
Noncontrolling interests 237  238  261  288  279 
Total equity 25,895  30,253  28,796  27,540  31,164 
Total liabilities and equity $ 652,120  $ 687,584  $ 677,576  $ 675,745  $ 704,976 
8

METLIFE
SUMMARY OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
   For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Adjusted earnings before provision for income tax
GROUP BENEFITS $ 645  $ 590  $ 359  $ 674  $ 472 
RIS 594  532  504  518  591 
ASIA 405  419  582  625  431 
LATIN AMERICA 282  271  331  311  309 
EMEA 112  63  103  98  94 
METLIFE HOLDINGS 259  193  196  188  226 
CORPORATE & OTHER (274) (341) (244) (233) (223)
Total adjusted earnings before provision for income tax
$ 2,023  $ 1,727  $ 1,831  $ 2,181  $ 1,900 
Provision for income tax expense (benefit)
GROUP BENEFITS $ 135  $ 124  $ 75  $ 141  $ 99 
RIS 124  111  105  108  119 
ASIA 130  123  159  176  125 
LATIN AMERICA 83  64  98  85  88 
EMEA 24  16  26  21  24 
METLIFE HOLDINGS 51  37  37  35  44 
CORPORATE & OTHER (79) (142) (70) (47) (41)
Total provision for income tax expense (benefit)
$ 468  $ 333  $ 430  $ 519  $ 458 
Adjusted earnings available to common shareholders
GROUP BENEFITS $ 510  $ 466  $ 284  $ 533  $ 373 
RIS 470  421  399  410  472 
ASIA 275  296  423  449  306 
LATIN AMERICA 199  207  233  226  221 
EMEA 88  47  77  77  70 
METLIFE HOLDINGS 208  156  159  153  182 
CORPORATE & OTHER (1) (262) (232) (241) (220) (249)
Total adjusted earnings available to common shareholders (1) $ 1,488  $ 1,361  $ 1,334  $ 1,628  $ 1,375 
(1)Includes impact of preferred stock dividends of $67 million, $33 million, $67 million, $34 million and $67 million for the three months ended September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively.
9

GROUP BENEFITS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted revenues
Premiums $ 5,276  $ 5,404  $ 5,711  $ 5,599  $ 5,538  $ 16,154  $ 16,848 
Universal life and investment-type product policy fees 219  218  222  229  231  660  682 
Net investment income 330  334  315  313  311  967  939 
Other revenues 371  379  397  382  377  1,114  1,156 
Total adjusted revenues 6,196  6,335  6,645  6,523  6,457  18,895  19,625 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 4,592  4,712  5,236  4,780  4,927  14,452  14,943 
Policyholder liability remeasurement (gains) losses (29) (3) —  (31) (1)
Interest credited to policyholder account balances 50  49  48  48  49  144  145 
Capitalization of DAC (5) (4) (4) (5) (4) (16) (13)
Amortization of DAC and VOBA 19  19 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt —  —  — 
Other expenses 937  977  1,003  1,016  1,007  2,819  3,026 
Total adjusted expenses 5,551  5,745  6,286  5,849  5,985  17,388  18,120 
Adjusted earnings before provision for income tax 645  590  359  674  472  1,507  1,505 
Provision for income tax expense (benefit) 135  124  75  141  99  318  315 
Adjusted earnings 510  466  284  533  373  1,189  1,190 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 510  $ 466  $ 284  $ 533  $ 373  $ 1,189  $ 1,190 
Adjusted premiums, fees and other revenues $ 5,866  $ 6,001  $ 6,330  $ 6,210  $ 6,146  $ 17,928  $ 18,686 
10

GROUP BENEFITS
OTHER EXPENSES BY MAJOR CATEGORY
   For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Direct and allocated expenses $ 464  $ 490  $ 505  $ 490  $ 486 
Pension, postretirement and postemployment benefit costs 12  12  14  14  14 
Premium taxes, other taxes, and licenses & fees 83  79  89  95  93 
Commissions and other variable expenses 378  396  395  417  414 
Adjusted other expenses $ 937  $ 977  $ 1,003  $ 1,016  $ 1,007 
OTHER STATISTICAL INFORMATION (1)
   For the Three Months Ended
Unaudited (In millions, except ratios) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Group Life (2)
Adjusted premiums, fees and other revenues $ 2,215  $ 2,199  $ 2,340  $ 2,309  $ 2,293 
Mortality ratio 83.6  % 83.5  % 90.2  % 79.1  % 85.6  %
Group Non-Medical Health (3)
Adjusted premiums, fees and other revenues $ 2,620  $ 2,689  $ 2,773  $ 2,742  $ 2,718 
Interest adjusted benefit ratio (4) 69.0  % 70.7  % 73.9  % 70.8  % 72.4  %
(1) Results are derived from insurance and non-administrative services-only contracts.
(2) Excludes certain experience-rated contracts and includes accidental death and dismemberment.
(3) Primarily includes dental, group and individual disability, accident & health, critical illness and vision.
(4) Reflects actual claims experience and excludes the impact of interest credited on future policyholder benefits. The product within Group Non-Medical Health with interest credited on future policyholder benefits is disability.
11

RIS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted revenues
Premiums $ 2,330  $ 2,736  $ 675  $ 2,448  $ 1,451  $ 5,512  $ 4,574 
Universal life and investment-type product policy fees 82  81  75  73  67  232  215 
Net investment income 2,009  2,032  2,089  2,117  2,133  5,771  6,339 
Other revenues 66  66  63  61  61  205  185 
Total adjusted revenues 4,487  4,915  2,902  4,699  3,712  11,720  11,313 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 3,100  3,503  1,471  3,248  2,247  7,766  6,966 
Policyholder liability remeasurement (gains) losses (76) (15) (23) (148) (116) (170)
Interest credited to policyholder account balances 756  783  796  838  874  2,104  2,508 
Capitalization of DAC (41) (40) (61) (46) (53) (136) (160)
Amortization of DAC and VOBA 13  13  15  16  14  36  45 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt 10  11 
Other expenses 138  135  172  145  183  430  500 
Total adjusted expenses 3,893  4,383  2,398  4,181  3,121  10,094  9,700 
Adjusted earnings before provision for income tax 594  532  504  518  591  1,626  1,613 
Provision for income tax expense (benefit) 124  111  105  108  119  339  332 
Adjusted earnings 470  421  399  410  472  1,287  1,281 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 470  $ 421  $ 399  $ 410  $ 472  $ 1,287  $ 1,281 
Adjusted premiums, fees and other revenues $ 2,478  $ 2,883  $ 813  $ 2,582  $ 1,579  $ 5,949  $ 4,974 
Less: PRT
1,461  1,860  (25) 1,752  529  3,464  2,256 
Adjusted premiums, fees and other revenues, excluding PRT $ 1,017  $ 1,023  $ 838  $ 830  $ 1,050  $ 2,485  $ 2,718 
12

RIS
FUTURE POLICY BENEFITS (1)
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Balance, end of period (at balance sheet discount rate) (2), (3) $ 61,947  $ 69,407  $ 67,402  $ 69,385  $ 72,914 
Less: Accumulated other comprehensive (income) loss (5,598) (278) (1,735) (2,952) 297 
Balance, end of period (at original discount rate) $ 67,545  $ 69,685  $ 69,137  $ 72,337  $ 72,617 
POLICYHOLDER ACCOUNT BALANCES
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Balance, end of period $ 80,929  $ 82,405  $ 83,049  $ 84,270  $ 85,410 
SEPARATE ACCOUNT LIABILITIES
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Balance, end of period $ 51,740  $ 53,093  $ 51,012  $ 50,033  $ 52,537 
SYNTHETIC GICS (4), (5)
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Balance, end of period $ 49,003  $ 49,066  $ 48,100  $ 48,982  $ 49,081 
LONGEVITY REINSURANCE (6)
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Balance, end of period $ 19,175  $ 21,945  $ 21,333  $ 24,422  $ 25,699 
(1)Includes $3,731 million, $3,782 million, $3,791 million, $3,830 million and $3,847 million of DPL at September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively.
(2)Represents the current discount rate at the respective balance sheet date.
(3)Includes $40 million, $311 million, $296 million, $1,972 million and $2,081 million of future policy benefits subject to reinsurance, which are included in premiums, reinsurance and other receivables on MetLife, Inc.'s consolidated balance sheets at September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively.
(4)A synthetic GIC is a contract that simulates the performance of a traditional GIC through the use of financial instruments and is reported as a derivative. A key difference between a synthetic GIC and a traditional GIC is that the contractholder owns the assets underlying the synthetic GIC. The assets and corresponding contractholder account balance are not on MetLife, Inc.'s consolidated balance sheet, as they are for a traditional GIC. The contractholder account balance is reported at contract value in the table above.
(5)Includes $0, $1,282 million, $0, $0 and $0 of transfers from separate account GICs to synthetic GICs at September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively.
(6)The contract value presented represents notional amounts based on the present value of fixed annuity premiums related to longevity reinsurance contracts associated with the United Kingdom pension risk transfer market.
13

RIS
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Direct and allocated expenses $ 66  $ 71  $ 80  $ 74  $ 75 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees 17  11  16 
Commissions and other variable expenses 59  60  71  57  88 
Adjusted other expenses $ 138  $ 135  $ 172  $ 145  $ 183 
SPREAD
For the Three Months Ended
Unaudited September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Investment income yield excluding variable investment income yield 5.28  % 5.32  % 5.24  % 5.28  % 5.25  %
Variable investment income yield 3.08  % 1.96  % 6.30  % 5.83  % 4.58  %
Total investment income yield 5.20  % 5.19  % 5.28  % 5.30  % 5.23  %
Average crediting rate 4.12  % 4.20  % 4.23  % 4.31  % 4.38  %
Amortization of DPL and losses at inception (1) (0.22) % (0.22) % (0.22) % (0.22) % (0.21) %
Total average crediting rate 3.90  % 3.98  % 4.01  % 4.09  % 4.17  %
Annualized general account spread 1.30  % 1.21  % 1.27  % 1.21  % 1.06  %
Annualized general account spread excluding variable investment income yield 1.38  % 1.34  % 1.23  % 1.19  % 1.08  %
(1)Includes the amortization of DPL of (0.23)%, (0.23)%, (0.23)%, (0.23)% and (0.23)% for the three months ended September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively.
14

ASIA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted revenues
Premiums $ 1,312  $ 1,252  $ 1,297  $ 1,216  $ 1,272  $ 3,999  $ 3,785 
Universal life and investment-type product policy fees 411  428  426  434  420  1,204  1,280 
Net investment income 1,023  1,003  1,108  1,167  1,132  2,954  3,407 
Other revenues 20  25  21  18  18  61  57 
Total adjusted revenues 2,766  2,708  2,852  2,835  2,842  8,218  8,529 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,095  1,051  1,067  988  1,035  3,282  3,090 
Policyholder liability remeasurement (gains) losses 108  13  (32) (4) 60  92  24 
Interest credited to policyholder account balances 576  619  647  657  683  1,682  1,987 
Capitalization of DAC (404) (381) (361) (335) (336) (1,202) (1,032)
Amortization of DAC and VOBA 204  207  210  207  217  587  634 
Amortization of negative VOBA (6) (5) (5) (5) (6) (17) (16)
Interest expense on debt —  —  —  —  —  —  — 
Other expenses 788  785  744  702  758  2,373  2,204 
Total adjusted expenses 2,361  2,289  2,270  2,210  2,411  6,797  6,891 
Adjusted earnings before provision for income tax 405  419  582  625  431  1,421  1,638 
Provision for income tax expense (benefit) 130  123  159  176  125  435  460 
Adjusted earnings 275  296  423  449  306  986  1,178 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 275  $ 296  $ 423  $ 449  $ 306  $ 986  $ 1,178 
Adjusted premiums, fees and other revenues $ 1,743  $ 1,705  $ 1,744  $ 1,668  $ 1,710  $ 5,264  $ 5,122 
15

ASIA
ADJUSTED PREMIUMS, FEES AND OTHER REVENUES
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Adjusted premiums, fees and other revenues $ 1,743  $ 1,705  $ 1,744  $ 1,668  $ 1,710 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,704  $ 1,690  $ 1,737  $ 1,714  $ 1,710 
Add: Operating joint ventures, on a constant currency basis (1) 428  367  527  654  541 
Adjusted premiums, fees and other revenues, including operating joint ventures, on a constant currency basis $ 2,132  $ 2,057  $ 2,264  $ 2,368  $ 2,251 
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Direct and allocated expenses $ 284  $ 300  $ 282  $ 272  $ 303 
Pension, postretirement and postemployment benefit costs 16  20  15  15  15 
Premium taxes, other taxes, and licenses & fees 33  34  33  28  31 
Commissions and other variable expenses 455  431  414  387  409 
Adjusted other expenses $ 788  $ 785  $ 744  $ 702  $ 758 
Adjusted other expenses, net of adjusted capitalization of DAC $ 384  $ 404  $ 383  $ 367  $ 422 
Adjusted other expenses on a constant currency basis $ 766  $ 777  $ 742  $ 727  $ 758 
Add: Operating joint ventures, on a constant currency basis (2) 114  98  115  107  120 
Adjusted other expenses, including operating joint ventures, on a constant currency basis $ 880  $ 875  $ 857  $ 834  $ 878 
Adjusted other expenses, including operating joint ventures, net of adjusted capitalization of DAC, on a constant currency basis
$ 464  $ 483  $ 449  $ 442  $ 487 
SALES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Japan:
Life $ 177  $ 194  $ 136  $ 138  $ 142 
Accident & Health 52  59  71  65  60 
Annuities 146  178  148  146  147 
Other
Total Japan 377  432  357  351  351 
Other Asia 218  178  224  288  239 
   Total sales $ 595  $ 610  $ 581  $ 639  $ 590 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Adjusted earnings available to common shareholders $ 275  $ 296  $ 423  $ 449  $ 306 
Adjusted earnings available to common shareholders, on a constant currency basis $ 271  $ 295  $ 423  $ 451  $ 306 
(1)Includes MetLife, Inc.'s share of adjusted premiums, fees and other revenues for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
(2)Includes MetLife, Inc.'s share of adjusted other expenses for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.

16

ASIA
ASIA GENERAL ACCOUNT ASSETS UNDER MANAGEMENT AND RELATED MEASURES
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
GA AUM $ 113,105  $ 123,434  $ 120,743  $ 117,606  $ 128,115 
GA AUM (at amortized cost) $ 124,684  $ 130,093  $ 128,618  $ 126,997  $ 135,107 
GA AUM (at amortized cost), on a constant currency basis $ 126,973  $ 129,294  $ 131,300  $ 132,191  $ 135,107 
  Add: Operating joint ventures, on a constant currency basis (1) 8,567  8,156  8,441  9,425  9,930 
GA AUM (at amortized cost), including operating joint ventures, on a constant currency basis $ 135,540  $ 137,450  $ 139,741  $ 141,616  $ 145,037 
(1)Includes MetLife, Inc.'s share of GA AUM for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
17

LATIN AMERICA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted revenues
Premiums $ 1,116  $ 1,123  $ 1,115  $ 1,122  $ 1,141  $ 3,164  $ 3,378 
Universal life and investment-type product policy fees 359  352  370  373  346  1,046  1,089 
Net investment income 365  482  386  398  435  1,162  1,219 
Other revenues 11  11  11  31  31 
Total adjusted revenues 1,849  1,968  1,882  1,904  1,931  5,403  5,717 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,020  1,132  983  1,018  1,091  2,962  3,092 
Policyholder liability remeasurement (gains) losses (4) (20) (8) (3) (18) (5) (29)
Interest credited to policyholder account balances 106  116  114  115  108  310  337 
Capitalization of DAC (171) (181) (178) (175) (174) (470) (527)
Amortization of DAC and VOBA 121  124  125  129  126  344  380 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt 11 
Other expenses 493  523  512  505  485  1,388  1,502 
Total adjusted expenses 1,567  1,697  1,551  1,593  1,622  4,537  4,766 
Adjusted earnings before provision for income tax 282  271  331  311  309  866  951 
Provision for income tax expense (benefit) 83  64  98  85  88  233  271 
Adjusted earnings 199  207  233  226  221  633  680 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 199  $ 207  $ 233  $ 226  $ 221  $ 633  $ 680 
Adjusted premiums, fees and other revenues $ 1,484  $ 1,486  $ 1,496  $ 1,506  $ 1,496  $ 4,241  $ 4,498 
18

LATIN AMERICA
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Direct and allocated expenses $ 148  $ 154  $ 140  $ 145  $ 129 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees 19  29  20  19  22 
Commissions and other variable expenses 325  339  350  340  333 
Adjusted other expenses $ 493  $ 523  $ 512  $ 505  $ 485 
Adjusted other expenses, net of adjusted capitalization of DAC $ 322  $ 342  $ 334  $ 330  $ 311 
Adjusted other expenses on a constant currency basis $ 449  $ 489  $ 477  $ 477  $ 485 
Adjusted other expenses, net of adjusted capitalization of DAC, on a constant currency basis $ 294  $ 321  $ 313  $ 313  $ 311 
SALES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Mexico $ 179  $ 150  $ 216  $ 193  $ 192 
Chile 91  95  96  99  106 
All other 72  77  71  81  85 
Total sales $ 342  $ 322  $ 383  $ 373  $ 383 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Adjusted premiums, fees and other revenues $ 1,484  $ 1,486  $ 1,496  $ 1,506  $ 1,496 
Adjusted earnings available to common shareholders $ 199  $ 207  $ 233  $ 226  $ 221 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,349  $ 1,393  $ 1,400  $ 1,422  $ 1,496 
Adjusted earnings available to common shareholders, on a constant currency basis $ 179  $ 192  $ 218  $ 210  $ 221 

19

EMEA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted revenues
Premiums $ 502  $ 519  $ 536  $ 536  $ 562  $ 1,497  $ 1,634 
Universal life and investment-type product policy fees 79  67  77  77  84  231  238 
Net investment income 51  54  54  54  55  143  163 
Other revenues 23  24 
Total adjusted revenues 639  649  674  675  710  1,894  2,059 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 230  256  258  265  276  728  799 
Policyholder liability remeasurement (gains) losses (9) —  (10) 10 
Interest credited to policyholder account balances 19  18  19  17  17  54  53 
Capitalization of DAC (114) (116) (128) (115) (119) (341) (362)
Amortization of DAC and VOBA 87  91  91  82  92  257  265 
Amortization of negative VOBA (1) (1) (1) (1) (1) (3) (3)
Interest expense on debt —  —  —  —  —  —  — 
Other expenses 315  331  332  328  342  929  1,002 
Total adjusted expenses 527  586  571  577  616  1,614  1,764 
Adjusted earnings before provision for income tax 112  63  103  98  94  280  295 
Provision for income tax expense (benefit) 24  16  26  21  24  62  71 
Adjusted earnings 88  47  77  77  70  218  224 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 88  $ 47  $ 77  $ 77  $ 70  $ 218  $ 224 
Adjusted premiums, fees and other revenues $ 588  $ 595  $ 620  $ 621  $ 655  $ 1,751  $ 1,896 
20

EMEA
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Direct and allocated expenses $ 104  $ 109  $ 101  $ 104  $ 109 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees
Commissions and other variable expenses 203  210  224  217  225 
Adjusted other expenses $ 315  $ 331  $ 332  $ 328  $ 342 
Adjusted other expenses, net of adjusted capitalization of DAC $ 201  $ 215  $ 204  $ 213  $ 223 
Adjusted other expenses on a constant currency basis $ 307  $ 327  $ 328  $ 332  $ 342 
Adjusted other expenses, net of adjusted capitalization of DAC, on a constant currency basis $ 197  $ 212  $ 202  $ 216  $ 223 
OTHER STATISTICAL INFORMATION
   For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Adjusted premiums, fees and other revenues $ 588  $ 595  $ 620  $ 621  $ 655 
Adjusted earnings available to common shareholders $ 88  $ 47  $ 77  $ 77  $ 70 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 573  $ 586  $ 613  $ 626  $ 655 
Adjusted earnings available to common shareholders, on a constant currency basis $ 87  $ 46  $ 76  $ 77  $ 70 
Total sales on a constant currency basis $ 189  $ 201  $ 282  $ 278  $ 249 
21

METLIFE HOLDINGS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted revenues
Premiums $ 685  $ 754  $ 713  $ 692  $ 673  $ 2,127  $ 2,078 
Universal life and investment-type product policy fees 184  95  78  94  80  537  252 
Net investment income 1,153  1,044  1,010  1,016  981  3,450  3,007 
Other revenues 41  52  50  37  40  143  127 
Total adjusted revenues 2,063  1,945  1,851  1,839  1,774  6,257  5,464 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,311  1,329  1,251  1,252  1,221  4,021  3,724 
Policyholder liability remeasurement (gains) losses (7) 20  17  (35) 28 
Interest credited to policyholder account balances 198  135  103  106  84  595  293 
Capitalization of DAC (5) (5) (5) (4) (4) (17) (13)
Amortization of DAC and VOBA 65  61  59  57  58  197  174 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt 10  11 
Other expenses 238  220  223  220  220  707  663 
Total adjusted expenses 1,804  1,752  1,655  1,651  1,548  5,541  4,854 
Adjusted earnings before provision for income tax 259  193  196  188  226  716  610 
Provision for income tax expense (benefit) 51  37  37  35  44  139  116 
Adjusted earnings 208  156  159  153  182  577  494 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 208  $ 156  $ 159  $ 153  $ 182  $ 577  $ 494 
Adjusted premiums, fees and other revenues $ 910  $ 901  $ 841  $ 823  $ 793  $ 2,807  $ 2,457 
22

METLIFE HOLDINGS
FUTURE POLICY BENEFITS (1)
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Annuities $ 1,508  $ 1,610  $ 1,577  $ 1,555  $ 1,606 
Life and Other 53,930  53,930  53,604  53,296  53,096 
Long Term Care 13,025  15,240  14,845  14,455  15,657 
Balance, end of period (at balance sheet discount rate) (2) $ 68,463  $ 70,780  $ 70,026  $ 69,306  $ 70,359 
Less:
Annuities $ (110) $ (18) $ (46) $ (65) $ (5)
Life and Other (120) 27  (2) (27) 31 
Long Term Care (1,754) 313  (215) (755) 339 
Accumulated other comprehensive (income) loss $ (1,984) $ 322  $ (263) $ (847) $ 365 
Annuities $ 1,618  $ 1,628  $ 1,623  $ 1,620  $ 1,611 
Life and Other 54,050  53,903  53,606  53,323  53,065 
Long Term Care 14,779  14,927  15,060  15,210  15,318 
Balance, end of period (at original discount rate) $ 70,447  $ 70,458  $ 70,289  $ 70,153  $ 69,994 
Future policy benefits subject to reinsurance (at balance sheet discount rate) (3)
Annuities $ —  $ 1,519  $ 1,526  $ 1,468  $ 1,505 
Life and Other $ 1,044  $ 2,341  $ 2,345  $ 2,372  $ 2,398 
Long Term Care $ —  $ —  $ —  $ —  $ — 
POLICYHOLDER ACCOUNT BALANCES
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Annuities $ 12,006  $ 11,537  $ 11,129  $ 10,747  $ 10,437 
Life and Other 11,844  11,641  11,486  11,303  11,284 
Balance, end of period $ 23,850  $ 23,178  $ 22,615  $ 22,050  $ 21,721 
Policyholder account balances subject to reinsurance (3)
Annuities $ —  $ 3,485  $ 3,345  $ 3,228  $ 3,124 
Life and Other $ 1,542  $ 6,352  $ 6,532  $ 6,467  $ 6,410 
MARKET RISK BENEFITS (4)
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Annuities $ 2,268  $ 2,722  $ 2,231  $ 2,153  $ 2,608 
Balance, end of period $ 2,268  $ 2,722  $ 2,231  $ 2,153  $ 2,608 
Market risk benefits subject to reinsurance $ —  $ —  $ —  $ —  $ — 
SEPARATE ACCOUNT LIABILITIES
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Annuities $ 27,455  $ 29,224  $ 29,866  $ 28,843  $ 29,349 
Life and Other 5,736  6,324  6,757  6,738  7,049 
Balance, end of period $ 33,191  $ 35,548  $ 36,623  $ 35,581  $ 36,398 
Separate accounts liabilities subject to modified coinsurance (5)
Annuities $ —  $ 83  $ 85  $ 82  $ 83 
Life and Other $ —  $ 5,597  $ 5,980  $ 5,944  $ 6,226 
(1) Includes participating life contracts, additional liabilities for annuitization, death and other insurance benefits, as well as DPL.
(2) Represents the current discount rate at the respective balance sheet date.
(3) Included in premiums, reinsurance and other receivables on MetLife, Inc.'s consolidated balance sheets.
(4) Market risk benefits include Japan reinsurance.
(5) Separate account assets retained by MetLife; these amounts are not included in premiums, reinsurance and other receivables on MetLife, Inc.'s consolidated balance sheets.
23

METLIFE HOLDINGS
OTHER EXPENSES BY MAJOR CATEGORY
   For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Direct and allocated expenses $ 166  $ 164  $ 165  $ 156  $ 159 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees 19  16  16  19  20 
Commissions and other variable expenses 48  34  36  38  35 
Adjusted other expenses $ 238  $ 220  $ 223  $ 220  $ 220 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions, except ratios) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Lapse Ratio (1)
Traditional life 5.1  % 5.4  % 5.7  % 5.9  % 6.2  %
Variable annuity 10.5  % 11.1  % 11.6  % 12.4  % 12.8  %
(1) Lapse ratios are calculated based on the average of the most recent 12 months of experience.

24

CORPORATE & OTHER
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Adjusted revenues
Premiums $ $ (2) $ $ 15  $ (6) $ 44  $ 15 
Universal life and investment-type product policy fees —  —  —  — 
Net investment income 125  98  106  95  96  255  297 
Other revenues 103  102  98  97  98  310  293 
Total adjusted revenues 237  198  210  208  188  610  606 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends (9) —  32  17 
Policyholder liability remeasurement (gains) losses —  —  —  —  —  —  — 
Interest credited to policyholder account balances —  —  —  —  —  —  — 
Capitalization of DAC (2) (1) (3) (3) (1) (7) (7)
Amortization of DAC and VOBA
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt 256  258  253  246  245  747  744 
Other expenses 250  290  194  188  164  656  546 
Total adjusted expenses 511  539  454  441  411  1,436  1,306 
Adjusted earnings before provision for income tax (274) (341) (244) (233) (223) (826) (700)
Provision for income tax expense (benefit) (79) (142) (70) (47) (41) (265) (158)
Adjusted earnings (195) (199) (174) (186) (182) (561) (542)
Preferred stock dividends 67  33  67  34  67  165  168 
Adjusted earnings available to common shareholders $ (262) $ (232) $ (241) $ (220) $ (249) $ (726) $ (710)
Adjusted premiums, fees and other revenues $ 112  $ 100  $ 104  $ 113  $ 92  $ 355  $ 309 
ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS BY SOURCE
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Business activities $ 13  $ 35  $ $ 30  $ 20  $ 52  $ 56 
Net investment income 126  95  102  92  96  258  290 
Interest expense on debt (266) (269) (265) (255) (256) (778) (776)
Corporate initiatives and projects (12) (9) (6) (7) (8) (58) (21)
Other (135) (193) (81) (93) (75) (300) (249)
Provision for income tax (expense) benefit and other tax-related items 79  142  70  47  41  265  158 
Preferred stock dividends (67) (33) (67) (34) (67) (165) (168)
Adjusted earnings available to common shareholders $ (262) $ (232) $ (241) $ (220) $ (249) $ (726) $ (710)
25

INVESTMENTS
INVESTMENT PORTFOLIO RESULTS BY ASSET CATEGORY AND ANNUALIZED YIELDS
This yield table presentation is consistent with how we measure our investment performance for management purposes, and we believe it enhances understanding of our investment portfolio results.
At or For the Three Months Ended At or For the Year-to-Date Period Ended
Unaudited (In millions, except yields) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Fixed Maturity Securities
Yield (1) 4.19  % 4.39  % 4.38  % 4.38  % 4.52  % 4.14  % 4.43  %
Investment income (2), (3) $ 3,123  $ 3,241  $ 3,200  $ 3,206  $ 3,357  $ 9,258  $ 9,763 
Investment gains (losses) (699) (197) (85) (246) (157) (2,275) (488)
Ending carrying value (4) 272,456  282,861  279,855  279,170  295,460  272,456  295,460 
Net Mortgage Loans
Yield (1) 5.18  % 5.36  % 5.25  % 5.30  % 5.32  % 5.07  % 5.29  %
Investment income (3) 1,094  1,127  1,100  1,096  1,097  3,226  3,293 
Investment gains (losses) (69) (82) (156) (129) (232)
Ending carrying value (5) 84,058  84,118  83,452  82,051  82,773  84,058  82,773 
Real Estate and Real Estate Joint Ventures
Yield (1) (0.31) % 2.08  % (2.74) % (0.97) % 1.67  % (0.54) % (0.65) %
Investment income (11) 69  (90) (32) 57  (53) (65)
Investment gains (losses) 37  35  12  128  32  175 
Ending carrying value 13,133  13,332  12,992  13,517  13,731  13,133  13,731 
Policy Loans
Yield (1) 5.52  % 5.36  % 5.56  % 5.44  % 5.72  % 5.42  % 5.57  %
Investment income 120  113  113  110  116  358  339 
Ending carrying value 8,725  8,788  8,800  8,691  8,822  8,725  8,822 
Equity Securities
Yield (1) 4.14  % 3.37  % 5.48  % 5.50  % 3.47  % 3.65  % 4.79  %
Investment income 27  18 
Investment gains (losses) (14) 15  28  (19) (31) 66  (22)
Ending carrying value 742  757  750  754  746  742  746 
Other Limited Partnership Interests
Yield (1), (6) 5.56  % (0.06) % 8.27  % 9.10  % 2.45  % 4.17  % 6.62  %
Investment income (6) 206  (2) 301  325  87  457  713 
Investment gains (losses) —  —  (50) (9) 12  (56)
Ending carrying value (7) 14,918  14,764  14,301  14,288  14,186  14,918  14,186 
Cash and Short-term Investments
Yield (1) 6.38  % 5.61  % 5.32  % 4.61  % 5.23  % 5.78  % 5.06  %
Investment income 220  229  246  209  257  582  712 
Investment gains (losses) (33) 25  37  (46) 23  16 
Ending carrying value 21,409  26,684  24,724  24,590  26,374  21,409  26,374 
Other Invested Assets
Investment income 420  410  348  386  312  1,256  1,046 
Investment gains (losses) (167) (17) (16) 56  (165) 23 
Ending carrying value 18,755  18,202  18,097  18,131  19,706  18,755  19,706 
Total Investments
Investment income yield (1) 4.68  % 4.69  % 4.75  % 4.83  % 4.75  % 4.55  % 4.77  %
Investment fees and expenses yield (1) (0.11) % (0.13) % (0.14) % (0.13) % (0.13) % (0.12) % (0.14) %
Net Investment Income Yield (1) 4.57  % 4.56  % 4.61  % 4.70  % 4.62  % 4.43  % 4.63  %
Investment income $ 5,177  $ 5,191  $ 5,225  $ 5,307  $ 5,287  $ 15,111  $ 15,819 
Investment fees and expenses (121) (144) (157) (147) (144) (409) (448)
Net investment income including divested businesses 5,056  5,047  5,068  5,160  5,143  14,702  15,371 
Less: Net investment income from divested businesses —  —  —  —  —  —  — 
Adjusted Net Investment Income (8) $ 5,056  $ 5,047  $ 5,068  $ 5,160  $ 5,143  $ 14,702  $ 15,371 
Ending Carrying Value $ 434,196  $ 449,506  $ 442,971  $ 441,192  $ 461,798  $ 434,196  $ 461,798 
Investment Portfolio Gains (Losses) (9) $ (871) $ (240) $ (146) $ (235) $ (203) $ (2,436) $ (584)
Gross investment gains 119  292  331  245  368  823  944 
Gross investment losses (418) (465) (435) (458) (417) (1,630) (1,310)
Net credit loss (provision) release and (impairments) (572) (67) (42) (22) (154) (1,629) (218)
Investment Portfolio Gains (Losses) (9) (871) (240) (146) (235) (203) (2,436) (584)
Investment portfolio gains (losses) income tax (expense) benefit 155  80  41  57  56  524  154 
Investment Portfolio Gains (Losses), Net of Income Tax $ (716) $ (160) $ (105) $ (178) $ (147) $ (1,912) $ (430)
Derivative gains (losses) (9) (1,454) (123) (1,175) (698) 619  (3,104) (1,254)
Derivative gains (losses) income tax (expense) benefit 397  (45) 304  193  (206) 764  291 
Derivative Gains (Losses), Net of Income Tax $ (1,057) $ (168) $ (871) $ (505) $ 413  $ (2,340) $ (963)
See footnotes on Page 29.

26

INVESTMENTS
 
SUMMARY OF FIXED MATURITY SECURITIES AVAILABLE-FOR-SALE
BY SECTOR AND QUALITY DISTRIBUTION
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Unaudited (In millions, except ratios) Amount % of Total Amount % of Total Amount % of Total Amount % of Total Amount % of Total
U.S. corporate $ 78,552  28.9  % $ 80,717  28.7  % $ 80,553  28.9  % $ 80,678  29.1  % $ 84,851  28.9  %
Foreign corporate 51,377  19.0  % 55,444  19.7  % 54,029  19.4  % 53,419  19.2  % 56,752  19.3  %
Foreign government 42,685  15.8  % 45,489  16.2  % 42,793  15.4  % 40,054  14.4  % 44,132  15.0  %
Residential mortgage-backed 27,785  10.3  % 29,096  10.3  % 31,142  11.2  % 32,616  11.7  % 35,264  12.0  %
U.S. government and agency 31,729  11.7  % 32,252  11.5  % 31,848  11.4  % 33,238  12.0  % 34,676  11.8  %
Asset-backed securities and collateralized loan obligations 17,412  6.4  % 17,294  6.1  % 17,468  6.3  % 17,775  6.4  % 17,520  6.0  %
Municipals 11,347  4.2  % 11,171  4.0  % 10,938  3.9  % 10,470  3.8  % 10,798  3.7  %
Commercial mortgage-backed 10,095  3.7  % 9,949  3.5  % 9,638  3.5  % 9,486  3.4  % 9,786  3.3  %
Fixed Maturity Securities Available-For-Sale $ 270,982  100.0  % $ 281,412  100.0  % $ 278,409  100.0  % $ 277,736  100.0  % $ 293,779  100.0  %
NRSRO NAIC
RATING DESIGNATION
Aaa / Aa / A 1 $ 186,834  69.0  % $ 194,722  69.2  % $ 192,127  69.0  % $ 192,239  69.2  % $ 203,560  69.3  %
Baa 2 71,043  26.2  % 73,680  26.2  % 73,367  26.4  % 72,732  26.2  % 77,031  26.2  %
Ba 3 10,325  3.8  % 10,299  3.7  % 10,323  3.7  % 9,189  3.3  % 9,666  3.3  %
B 4 2,343  0.9  % 2,371  0.8  % 2,259  0.8  % 3,291  1.2  % 3,131  1.1  %
Caa and lower 5 338  0.1  % 258  0.1  % 267  0.1  % 226  0.1  % 331  0.1  %
In or near default 6 99  —  % 82  —  % 66  —  % 59  —  % 60  —  %
Total Fixed Maturity Securities Available-For-Sale (10) $ 270,982  100.0  % $ 281,412  100.0  % $ 278,409  100.0  % $ 277,736  100.0  % $ 293,779  100.0  %
GROSS UNREALIZED GAINS AND LOSSES:
FIXED MATURITY SECURITIES AVAILABLE-FOR-SALE
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Gross unrealized gains $ 3,685  $ 6,876  $ 6,021  $ 5,096  $ 8,093 
Gross unrealized losses 38,702  25,835  28,122  30,430  23,558 
Net Unrealized Gains (Losses) $ (35,017) $ (18,959) $ (22,101) $ (25,334) $ (15,465)
See footnotes on Page 29.

27

INVESTMENTS
SUMMARY OF NET MORTGAGE LOANS (5)
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
              
Commercial mortgage loans $ 52,053  $ 52,111  $ 51,527  $ 50,109  $ 50,478 
Agricultural mortgage loans 19,658  19,559  19,461  19,383  19,210 
Residential mortgage loans 12,986  13,096  13,201  13,273  13,844 
Total 84,697  84,766  84,189  82,765  83,532 
Allowance for credit loss (639) (648) (737) (714) (759)
Net Mortgage Loans $ 84,058  $ 84,118  $ 83,452  $ 82,051  $ 82,773 
SUMMARY OF NET COMMERCIAL MORTGAGE LOANS
BY REGION AND PROPERTY TYPE (5)
 
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Unaudited (In millions, except ratios) Amount % of Total Amount % of Total Amount % of Total Amount % of Total Amount % of Total
Pacific $ 9,206  17.7  % $ 9,016  17.3  % $ 9,036  17.5  % $ 8,680  17.3  % $ 8,745  17.3  %
Non-U.S. 8,682  16.7  % 8,933  17.1  % 8,453  16.4  % 8,385  16.7  % 8,593  17.0  %
Middle Atlantic 7,581  14.6  % 7,477  14.3  % 7,430  14.4  % 7,250  14.5  % 6,999  13.9  %
South Atlantic 6,581  12.6  % 6,637  12.7  % 6,802  13.2  % 6,517  13.0  % 6,459  12.8  %
West South Central 3,417  6.6  % 3,472  6.7  % 3,502  6.8  % 3,386  6.8  % 3,455  6.9  %
New England 2,875  5.5  % 2,859  5.5  % 2,821  5.5  % 2,821  5.6  % 2,838  5.6  %
Mountain 2,191  4.2  % 2,193  4.2  % 2,192  4.3  % 2,264  4.5  % 2,217  4.4  %
East North Central 1,855  3.6  % 1,822  3.5  % 1,701  3.3  % 1,600  3.2  % 1,543  3.1  %
East South Central 622  1.2  % 654  1.3  % 653  1.3  % 652  1.3  % 608  1.2  %
West North Central 643  1.2  % 613  1.2  % 644  1.2  % 472  1.0  % 472  0.9  %
Multi-Region and Other 8,400  16.1  % 8,435  16.2  % 8,293  16.1  % 8,082  16.1  % 8,549  16.9  %
Total $ 52,053  100.0  % $ 52,111  100.0  % $ 51,527  100.0  % $ 50,109  100.0  % $ 50,478  100.0  %
Office $ 19,619  37.7  % $ 19,651  37.7  % $ 19,369  37.6  % $ 18,799  37.5  % $ 18,861  37.4  %
Apartment 11,807  22.7  % 11,974  23.0  % 11,353  22.0  % 10,954  21.9  % 10,750  21.3  %
Retail 7,441  14.3  % 7,218  13.9  % 7,371  14.3  % 7,443  14.8  % 7,273  14.4  %
Industrial 5,248  10.1  % 5,275  10.1  % 5,315  10.3  % 4,941  9.9  % 5,313  10.5  %
Single Family Rental 4,735  9.1  % 4,728  9.1  % 4,823  9.4  % 4,822  9.6  % 5,141  10.2  %
Hotel 3,088  5.9  % 3,140  6.0  % 3,199  6.2  % 3,049  6.1  % 3,051  6.0  %
Other 115  0.2  % 125  0.2  % 97  0.2  % 101  0.2  % 89  0.2  %
Total $ 52,053  100.0  % $ 52,111  100.0  % $ 51,527  100.0  % $ 50,109  100.0  % $ 50,478  100.0  %
See footnotes on Page 29.
28

INVESTMENTS
FOOTNOTES
(1)We calculate annualized yields using adjusted net investment income as a percent of average quarterly asset carrying values. Adjusted net investment income excludes realized gains and losses from sales and disposals, includes the impact of changes in foreign currency exchange rates and reflects the adjustments described on Page A-7 and presented on Page A-1. Asset carrying values utilized in the calculation of yields exclude unrecognized unrealized gains (losses), mortgage loans originated for third parties, collateral received in connection with our securities lending program, annuities funding structured settlement claims, freestanding derivative assets, collateral received from derivative counterparties and contractholder-directed equity securities. Invested assets reclassified to held-for-sale and ceded policy loans are included in the calculation of yields, but are otherwise excluded from asset carrying values. A yield is not presented for other invested assets, as it is not considered a meaningful measure of performance for this asset class.
(2)Fixed maturity securities includes investment income related to fair value option securities of ($17) million, $107 million, $85 million, $22 million and $76 million for the three months ended September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively, and $81 million and $183 million for the year-to-date period ended September 30, 2023 and September 30, 2024, respectively.
(3)Investment income from fixed maturity securities and net mortgage loans includes prepayment fees.
(4)The following table presents the components of total fixed maturity securities and a reconciliation to ending carrying value presented for fixed maturity securities.
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Fixed maturity securities available-for-sale $ 270,982  $ 281,412  $ 278,409  $ 277,736  $ 293,779 
Contractholder-directed equity securities and fair value option securities 9,680  10,331  10,313  10,106  9,289 
Total fixed maturity securities 280,662  291,743  288,722  287,842  303,068 
Less: Contractholder-directed equity securities 8,206  8,882  8,867  8,672  7,608 
Fixed maturity securities $ 272,456  $ 282,861  $ 279,855  $ 279,170  $ 295,460 
(5)Net mortgage loans exclude mortgage loans originated for third parties of $8,238 million, $8,461 million, $8,083 million, $7,843 million, and $7,730 million at amortized cost, which is primarily comprised of commercial mortgage loans of $7,998 million, $8,215 million, $7,832 million, $7,590 million and $7,471 million at amortized cost, and does not include the related allowance for credit loss of $66 million, $73 million, $77 million, $92 million and $88 million at September 30, 2023, December 31, 2023, March 31, 2024 , June 30, 2024 and September 30, 2024, respectively.
(6)Other limited partnership interests includes investment income related to private equity investments of $203 million, ($2) million, $301 million, $326 million and $87 million for the three months ended September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively, and $443 million and $714 million for the year-to-date period ended September 30, 2023 and September 30, 2024, respectively. The annualized yields for these periods were 5.50%, (0.06%), 8.29%, 9.13%, 2.46%, 4.09% and 6.64%, respectively.
(7)Other limited partnership interests includes ending carrying value related to private equity investments of $14,862 million, $14,738 million, $14,276 million, $14,270 million and $14,168 million, at September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, respectively.
(8)Adjusted net investment income reflects the adjustments as presented on Page 5.
(9)Investment portfolio gains (losses) and Derivative gains (losses) reflect the non-GAAP adjustments as presented below:
For the Three Months Ended For the Year-to-Date Period Ended
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Net investment gains (losses) $ (927) $ (174) $ (375) $ (421) $ (77) $ (2,650) $ (873)
Less: Non-investment portfolio gains (losses) (63) 64  (226) (176) 188  (145) (214)
Less: Provision for credit loss on certain mortgage loans originated for third parties (7) (4) (15) (66) (15)
Less: Other adjustments —  (66) (3) (60)
Investment portfolio gains (losses) $ (871) $ (240) $ (146) $ (235) $ (203) $ (2,436) $ (584)
For the Three Months Ended For the Year-to-Date Period Ended
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Net derivative gains (losses) $ (1,202) $ 149  $ (979) $ (508) $ 767  $ (2,289) $ (720)
Less: Investment hedge adjustments 232  253  176  172  129  759  477 
Less: Other adjustments 20  19  20  18  19  56  57 
Derivative gains (losses) $ (1,454) $ (123) $ (1,175) $ (698) $ 619  $ (3,104) $ (1,254)
(10)Fixed maturity securities available-for-sale are presented by NRSRO rating and the applicable NAIC designation from the NAIC published comparison of NRSRO ratings to NAIC designations, except for (i) non-agency residential mortgage-backed securities (“RMBS”) and commercial mortgage-backed securities (“CMBS”) and (ii) securities rated Ca or C by NRSROs that are designated NAIC 6. NRSRO ratings are based on availability of applicable ratings. If no NRSRO rating is available, then an internally developed rating is used. Over time, credit ratings and designations can migrate, up or down, through the NRSRO's and NAIC's continuous monitoring process. Amounts presented for non-agency RMBS and CMBS are presented using NAIC designations for modeled securities. The NAIC evaluates non-agency RMBS and CMBS held by insurers on an annual basis. When we acquire non-agency RMBS and CMBS that have not been previously evaluated by the NAIC, an internally developed designation is used until a NAIC designation becomes available. NAIC designations are generally similar to the credit quality ratings of the NRSRO, except for (i) non-agency RMBS and CMBS and (ii) securities rated Ca or C by NRSROs that are designated NAIC 6; accordingly, NAIC designations may not correspond to NRSRO ratings.
29

image0a45a.jpg
Appendix






APPENDIX
METLIFE
RECONCILIATION DETAIL
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Reconciliation to Adjusted Earnings Available to Common Shareholders
Net income (loss) available to MetLife, Inc.'s common shareholders $ 422  $ 574  $ 800  $ 912  $ 1,275  $ 806  $ 2,987 
Add: Preferred stock dividends 67  33  67  34  67  165  168 
Add: Preferred stock redemption premium —  —  —  —  —  —  — 
Add: Net income (loss) attributable to noncontrolling interests (1) 17  14 
Net income (loss) 495  614  875  953  1,341  $ 988  $ 3,169 
Less: adjustments from net income (loss) to adjusted earnings:
Net investment gains (losses) (927) (174) (375) (421) (77) (2,650) (873)
Net derivative gains (losses) (1,202) 149  (979) (508) 767  (2,289) (720)
Market risk benefit remeasurement gains (losses) 796  (431) 694  182  (531) 1,425  345 
Premiums - Divested businesses
—  —  —  —  16  —  16 
Universal life and investment-type product policy fees - Divested businesses
—  —  —  —  —  —  — 
Net investment income
Investment hedge adjustments (232) (253) (176) (172) (129) (759) (477)
Unit-linked contract income 580  542  219  147  603  908 
Other adjustments (3) (8) (2) 66  (4) 66 
Divested businesses —  —  —  —  —  —  — 
Other revenues
Asymmetrical and non-economic accounting —  29  39  35  50  —  124 
Other adjustments (11) (13) (12) (11) (14) (21) (37)
Divested businesses —  —  —  —  —  —  — 
Policyholder benefits and claims and policyholder dividends
Asymmetrical and non-economic accounting (26) (14) (161) (153) (168)
Market volatility 64  62  67  88  52  122  207 
Divested businesses —  —  —  —  (9) —  (9)
Policyholder liability remeasurement (gains) losses - Divested businesses
—  —  —  —  —  —  — 
Interest credited to policyholder account balances
Asymmetrical and non-economic accounting 44  (103) (24) (5) (79) 35  (108)
Unit-linked contract costs (582) (539) (214) (143) (601) (896)
Divested businesses —  —  —  —  —  —  — 
Capitalization of DAC - Divested businesses
—  —  —  —  —  —  — 
Amortization of DAC and VOBA - Divested businesses
—  —  —  —  —  —  — 
Amortization of negative VOBA - Divested business
—  —  —  —  —  —  — 
Interest expense on debt - Divested business
—  —  —  —  —  —  — 
Other expenses
Other adjustments (21) (7) (7) (5) (12) (48) (24)
Divested businesses (9) (9) (4) (4) (17) (29) (25)
Goodwill impairment —  —  —  —  —  —  — 
Provision for income tax (expense) benefit 429  260  270  (195) 1,028  335 
Adjusted earnings 1,555  1,394  1,401  1,662  1,442  4,329  4,505 
Less: Preferred stock dividends 67  33  67  34  67  165  168 
Adjusted earnings available to common shareholders $ 1,488  $ 1,361  $ 1,334  $ 1,628  $ 1,375  $ 4,164  $ 4,337 
A-1

APPENDIX
METLIFE
NOTABLE ITEMS (1)
METLIFE TOTAL
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Actuarial assumption review and other insurance adjustments $ 14  $ —  $ —  $ —  $ 16  $ 14  $ 16 
Litigation reserves and settlement costs —  (76) —  —  —  —  — 
Total notable items $ 14  $ (76) $ —  $ —  $ 16  $ 14  $ 16 
GROUP BENEFITS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Actuarial assumption review and other insurance adjustments $ 27  $ —  $ —  $ —  $ (58) $ 27  $ (58)
Total notable items $ 27  $ —  $ —  $ —  $ (58) $ 27  $ (58)
RIS
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Actuarial assumption review and other insurance adjustments $ 61  $ —  $ —  $ —  $ 104  $ 61  $ 104 
Total notable items $ 61  $ —  $ —  $ —  $ 104  $ 61  $ 104 
(1)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results.
A-2

APPENDIX
METLIFE
NOTABLE ITEMS (1) (CONTINUED)
ASIA
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Actuarial assumption review and other insurance adjustments
$ (94) $ —  $ —  $ —  $ (41) $ (94) $ (41)
Total notable items
$ (94) $ —  $ —  $ —  $ (41) $ (94) $ (41)
LATIN AMERICA
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ —  $ —  $ $ —  $
Total notable items
$ —  $ —  $ —  $ —  $ $ —  $
EMEA
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Actuarial assumption review and other insurance adjustments
$ 18  $ —  $ —  $ —  $ (5) $ 18  $ (5)
Total notable items
$ 18  $ —  $ —  $ —  $ (5) $ 18  $ (5)
METLIFE HOLDINGS
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Actuarial assumption review and other insurance adjustments
$ $ —  $ —  $ —  $ 12  $ $ 12 
Total notable items
$ $ —  $ —  $ —  $ 12  $ $ 12 
CORPORATE & OTHER
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 September 30, 2023 September 30, 2024
Litigation reserves and settlement costs —  (76) —  —  —  —  — 
Total notable items $ —  $ (76) $ —  $ —  $ —  $ —  $ — 
(1)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results.
A-3

APPENDIX
METLIFE
EQUITY DETAILS, BOOK VALUE DETAILS AND RETURN ON EQUITY
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Total MetLife, Inc.'s stockholders' equity $ 25,658  $ 30,015  $ 28,535  $ 27,252  $ 30,885 
Less: Preferred stock 3,818  3,818  3,818  3,818  3,818 
MetLife, Inc.'s common stockholders' equity 21,840  26,197  24,717  23,434  27,067 
Less: Net unrealized investment gains (losses), net of income tax (26,548) (14,323) (16,611) (19,088) (11,531)
  Future policy benefits discount rate remeasurement gains (losses), net of income tax 10,245  2,658  4,773  6,606  2,004 
  Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax (4) 27  (47) (73)
  Defined benefit plans adjustment, net of income tax (1,308) (1,446) (1,421) (1,396) (1,371)
Total MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA 39,455  39,281  38,023  37,385  37,961 
Less: Accumulated year-to-date total notable items (2) 14  (62) —  —  16 
Total MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 39,441  $ 39,343  $ 38,023  $ 37,385  $ 37,945 
Unaudited (In millions, except per share data) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Book value per common share $ 29.34  $ 35.85  $ 34.54  $ 33.30  $ 39.02 
Less: Net unrealized investment gains (losses), net of income tax (35.66) (19.60) (23.21) (27.12) (16.62)
  Future policy benefits discount rate remeasurement gains (losses), net of income tax 13.77  3.64  6.68  9.38  2.89 
  Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax (0.01) 0.04  (0.07) (0.10) 0.01 
  Defined benefit plans adjustment, net of income tax (1.76) (1.98) (1.99) (1.98) (1.98)
Book value per common share, excluding AOCI other than FCTA $ 53.00  $ 53.75  $ 53.13  $ 53.12  $ 54.72 
Common shares outstanding, end of period 744.4  730.8  715.7  703.8  693.7 
For the Three Months Ended (1)
Unaudited (In millions, except ratios) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
Return on MetLife, Inc.'s:
Common stockholders' equity 7.0  % 9.6  % 12.6  % 15.2  % 20.2  %
Adjusted return on MetLife, Inc.'s:
Common stockholders' equity 24.7  % 22.7  % 21.0  % 27.0  % 21.8  %
Common stockholders' equity, excluding AOCI other than FCTA 14.9  % 13.8  % 13.8  % 17.3  % 14.6  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) 14.7  % 14.6  % 13.8  % 17.3  % 14.4  %
Average common stockholders' equity $ 24,142  $ 24,019  $ 25,457  $ 24,076  $ 25,251 
Average common stockholders' equity, excluding AOCI other than FCTA $ 40,001  $ 39,368  $ 38,652  $ 37,704  $ 37,673 
Average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 39,994  $ 39,392  $ 38,652  $ 37,704  $ 37,665 
(1) Annualized using quarter-to-date results.
(2)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Pages A-2 and A-3 for further detail.
A-4

APPENDIX
METLIFE
ADJUSTED PREMIUMS, FEES AND OTHER REVENUES, OTHER EXPENSES AND ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS - CONSTANT CURRENCY BASIS
 ADJUSTED PREMIUMS, FEES AND OTHER REVENUES, ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
GROUP BENEFITS (1) $ 5,866  $ 6,001  $ 6,330  $ 6,210  $ 6,146 
RIS (1) 2,478  2,883  813  2,582  1,579 
ASIA 1,704  1,690  1,737  1,714  1,710 
LATIN AMERICA 1,349  1,393  1,400  1,422  1,496 
EMEA 573  586  613  626  655 
METLIFE HOLDINGS (1) 910  901  841  823  793 
CORPORATE & OTHER (1) 112  100  104  113  92 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 12,992  $ 13,554  $ 11,838  $ 13,490  $ 12,471 
Adjusted premiums, fees and other revenues $ 13,181  $ 13,671  $ 11,948  $ 13,523  $ 12,471 
ASIA (including operating joint ventures) (2), (3) $ 2,132  $ 2,057  $ 2,264  $ 2,368  $ 2,251 
 OTHER EXPENSES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
GROUP BENEFITS (1) $ 937  $ 977  $ 1,003  $ 1,016  $ 1,007 
RIS (1) 138  135  172  145  183 
ASIA 766  777  742  727  758 
LATIN AMERICA 449  489  477  477  485 
EMEA 307  327  328  332  342 
METLIFE HOLDINGS (1) 238  220  223  220  220 
CORPORATE & OTHER (1) 250  290  194  188  164 
Adjusted other expenses on a constant currency basis $ 3,085  $ 3,215  $ 3,139  $ 3,105  $ 3,159 
Adjusted other expenses $ 3,159  $ 3,261  $ 3,180  $ 3,104  $ 3,159 
ASIA (including operating joint ventures) (2), (4) $ 880  $ 875  $ 857  $ 834  $ 878 
 ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024
GROUP BENEFITS (1) $ 510  $ 466  $ 284  $ 533  $ 373 
RIS (1) 470  421  399  410  472 
ASIA 271  295  423  451  306 
LATIN AMERICA 179  192  218  210  221 
EMEA 87  46  76  77  70 
METLIFE HOLDINGS (1) 208  156  159  153  182 
CORPORATE & OTHER (1) (262) (232) (241) (220) (249)
Adjusted earnings available to common shareholders on a constant currency basis $ 1,463  $ 1,344  $ 1,318  $ 1,614  $ 1,375 
Adjusted earnings available to common shareholders $ 1,488  $ 1,361  $ 1,334  $ 1,628  $ 1,375 
(1) Amounts on a reported basis, as constant currency impact is not significant.
(2) Adjusted premiums, fees and other revenues as well as other expenses are reported as part of net investment income on the statements of adjusted earnings available to common shareholders on Page 15 for operating joint ventures.
(3) Includes MetLife, Inc.'s share of adjusted premiums, fees and other revenues for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
(4) Includes MetLife, Inc.'s share of adjusted other expenses for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
A-5

APPENDIX
METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES

In this QFS, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of our business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.

The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
Non-GAAP financial measures: Comparable GAAP financial measures:
(i) total adjusted revenues (i) total revenues
(ii) total adjusted expenses (ii) total expenses
(iii) adjusted premiums, fees and other revenues (iii) premiums, fees and other revenues
(iv) adjusted premiums, fees and other revenues, excluding PRT (iv) premiums, fees and other revenues
(v) adjusted net investment income (v) net investment income
(vi) adjusted earnings (vi) net income (loss)
(vii) adjusted earnings available to common shareholders (vii) net income (loss) available to MetLife, Inc.’s common shareholders
(viii) adjusted earnings available to common shareholders, excluding total notable items (viii) net income (loss) available to MetLife, Inc.’s common shareholders
(ix) adjusted earnings available to common shareholders per diluted common share (ix) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share
(x) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share (x) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share
(xi) adjusted return on equity (xi) return on equity
(xii) adjusted return on equity, excluding AOCI other than FCTA (xii) return on equity
(xiii) adjusted return on equity, excluding total notable items (excludes AOCI other than FCTA) (xiii) return on equity
(xiv) investment portfolio gains (losses) (xiv) net investment gains (losses)
(xv) derivative gains (losses) (xv) net derivative gains (losses)
(xvi) adjusted capitalization of DAC (xvi) capitalization of DAC
(xvii) total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA (xvii) total MetLife, Inc.’s stockholders’ equity
(xviii) total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA) (xviii) total MetLife, Inc.’s stockholders’ equity
(xix) book value per common share, excluding AOCI other than FCTA (xix) book value per common share
(xx) adjusted other expenses (xx) other expenses
(xxi) adjusted other expenses, net of adjusted capitalization of DAC (xxi) other expenses, net of capitalization of DAC
(xxii) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (xxii) other expenses, net of capitalization of DAC
(xxiii) adjusted expense ratio (xxiii) expense ratio
(xxiv) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (xxiv) expense ratio
(xxv) direct expenses (xxv) other expenses
(xxvi) direct expenses, excluding total notable items related to direct expenses (xxvi) other expenses
(xxvii) direct expense ratio (xxvii) expense ratio
(xxviii) direct expense ratio, excluding total notable items related to direct expenses and PRT (xxviii) expense ratio
(xxix) future policy benefits at original discount rate (xxix) future policy benefits at balance sheet discount rate
Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the current period and applied to the comparable prior period ("constant currency basis").
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this QFS and in this period’s earnings news release, which is available at the MetLife Investor Relations webpage (https://investor.metlife.com).

A-6

APPENDIX
METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES (CONTINUED)
Our definitions of non-GAAP and other financial measures discussed in this QFS may differ from those used by other companies:

Adjusted earnings and related measures
adjusted earnings;
adjusted earnings available to common shareholders;
adjusted earnings available to common shareholders, excluding total notable items;
adjusted earnings available to common shareholders per diluted common share;
adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and
adjusted earnings available to common shareholders on a constant currency basis.
These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results.

Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.
Adjusted revenues and adjusted expenses
These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.

Market volatility can have a significant impact on MetLife’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.
Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments").
Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance.
Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance.
Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.
Other adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs").
Other revenues include fee revenue on synthetic GICs accounted for as freestanding derivatives.
Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium, which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders.
A-7


APPENDIX
METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES (CONTINUED)
Investment portfolio gains (losses) and derivative gains (losses)
These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).
Return on equity and related measures
Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment components of AOCI, net of income tax.
Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, and total notable items, net of income tax.
Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.'s average common stockholders’ equity.
Adjusted return on MetLife, Inc.’s common stockholders’ equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity.
Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity, excluding AOCI other than FCTA.
Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA).
The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses.
Expense ratio, direct expense ratio, adjusted expense ratio and related measures
Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.
Direct expense ratio: adjusted direct expenses divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third-party staffing costs, and general and administrative expenses.
Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Asia general account assets under management and related measures
Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio. Asia GA AUM is stated at estimated fair value and is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties, assets subject to reinsurance arrangements with third-party reinsurers, and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties ("net mortgage loans") (including commercial ("net commercial mortgage loans"), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.

Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on net mortgage loans (including net commercial mortgage loans, net agricultural mortgage loans and residential mortgage loans) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.
Other items
The following additional information is relevant to an understanding of our performance results:
Statistical sales information for Latin America, Asia and EMEA: calculated using 10% of single premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group). Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.
A-8

APPENDIX
METLIFE
ACRONYMS
 
AOCI Accumulated other comprehensive income (loss)
DAC Deferred policy acquisition costs
DPL Deferred profit liabilities
EMEA Europe, the Middle East and Africa
FCTA Foreign currency translation adjustments
GA General account
GA AUM General account assets under management
GAAP Accounting principles generally accepted in the United States of America
GICs Guaranteed interest contracts
NAIC National Association of Insurance Commissioners
NRSRO Nationally Recognized Statistical Rating Organization
PRT Pension risk transfers
QFS Quarterly financial supplement
RIS Retirement and Income Solutions
VOBA Value of business acquired
A-9


image0a45a.jpg
navigatinglifetogethera04a.jpg

EX-99.3 4 ex993q32024totalaum.htm EX-99.3 ex993q32024totalaum
Assets Under Management September 30, 2024 Investors turn to MetLife Investment Management for our client-centric approach and deep, long-established expertise in Fixed Income, Private Capital and Real Estate. We aim to deliver strong, risk-adjusted returns by building sustainable, tailored portfolio solutions. Our hallmark is approachable expertise – a commitment to being accountable and collaborative in helping clients realize their objectives. Total Assets Under Management1 By Asset Type $609.3 Billion Mortgage Loans $109.3 Public Corporates $103.6 Structured Products $70.2 Private Corporates $59.7 U.S. Government and Agency $54.3 Foreign Government $38.9 Private Infrastructure $37.8 Cash and Short-Term Investments $28.4 Real Estate Equity $24.2 Common and Preferred Equity $20.0 Alternatives $17.3 Emerging Market Debt $14.1 Municipals $12.6 Private Structured Credit $7.0 Bank Loans $5.9 High Yield $4.7 Middle Market Private Capital $1.3 Institutional Client Assets Under Management1 $177.1 Billion Insurance/Financial $82.2 Sub-Advisory $39.2 Corporate $26.7 Public $13.6 Commingled Fund2 $12.8 Other3 $2.6 1 As of September 30, 2024. At estimated fair value. Dollars in billions. Cash and Short-Term Investments includes cash equivalents. See Explanatory Note. 2 Includes limited partnerships, collective trusts, mutual funds registered under the Investment Company Act and other vehicles offered or available to qualifying investors, including third parties and affiliates. 3 Includes non-profit clients, Taft-Hartley pension fund clients and asset manager clients. 455 Mandates Representative Capabilities Private Capital Corporate Private Credit Infrastructure Debt Private Structured Credit Middle Market Private Capital Residential Whole Loans Private Equity Fixed Income Bank Loans Core Core Plus Corporate Emerging Market Debt High Yield Liability Driven Investing (LDI) Strategies Multi-Sector Short Duration Stable Value Real Estate Commercial Mortgage Loans Real Estate Equity Index Strategies Insurance Advisory 42% 19% 17% 11% 6% 5% Mandates Profile Institutional Client AUM investments.metlife.com Exhibit 99.3


 
Explanatory Note The following information is relevant to an understanding of our assets under management ("AUM") managed by MetLife Investment Management, LLC and certain of its affiliates ("MIM"). MIM is MetLife, Inc.'s institutional investment management business. Our definitions may differ from those used by other companies. Total Assets Under Management (“Total AUM”) is comprised of GA AUM plus Institutional Client AUM (each, as defined below). General Account AUM (“GA AUM”) is used by MetLife to describe assets in its general account ("GA") investment portfolio. GA AUM is stated at estimated fair value and is comprised of GA total investments, the portion of the GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties, assets subject to reinsurance arrangements with third-party reinsurers, and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties (“net mortgage loans”) (including commercial (“net commercial mortgage loans”), agricultural (“net agricultural mortgage loans”) and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. Classification of GA AUM by sector is based on the nature and characteristics of the underlying investments which can vary from how they are classified under GAAP. Accordingly, the underlying investments within certain real estate and real estate joint ventures that are primarily net commercial mortgage loans (at net asset value, net of deduction for encumbering debt) have been reclassified to exclude them from real estate equity and include them as net commercial mortgage loans. Institutional Client AUM is comprised of SA AUM plus Reinsurance AUM plus TP AUM (each, as defined below). MIM manages Institutional Client AUM in accordance with client guidelines contained in each investment advisory agreement (“Mandates”). Separate Account AUM (“SA AUM”) is comprised of separate account investment portfolios of MetLife insurance companies, which are managed by MIM and included in MetLife, Inc.’s consolidated financial statements at estimated fair value. Reinsurance AUM is comprised of GA investments subject to reinsurance arrangements with third-party reinsurers, which are managed by MIM and are generally included in MetLife, Inc.'s consolidated financial statements at estimated fair value. Third-Party AUM (“TP AUM”) is comprised of non-proprietary assets managed by MIM on behalf of unaffiliated/third-party clients, which are stated at estimated fair value. Such non-proprietary assets are owned by unaffiliated/third-party clients and, accordingly, are generally not included in MetLife, Inc.’s consolidated financial statements. Additional information about MetLife’s general account investment portfolio is available in MetLife, Inc.’s quarterly financial materials for the quarter ended September 30, 2024, which may be accessed through MetLife’s Investor Relations web page at https://investor.metlife.com. Neither MetLife, Inc.’s quarterly financial materials, nor any other information from the MetLife website, is a part of or incorporated by reference into this Total AUM Fact Sheet. Cautionary Statement on Forward-Looking Statements The forward-looking statements in this fact sheet, using words such as "aim," are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife's future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements. L1024044218[exp1025][All States] One MetLife Way | Whippany, New Jersey 07981 © 2023 METLIFE, INC.


 
EX-99.4 5 ex9943q24supplementalsli.htm EX-99.4 ex9943q24supplementalsli
3Q24 Supplemental Slides1 John McCallion Chief Financial Officer and Head of MetLife Investment Management Exhibit 99.4 1 These slides highlight information in MetLife, Inc.'s earnings release, quarterly financial supplement and other prior public disclosures.


 
2 Table of contents Topic Page No. Net income (loss) to adjusted earnings 3 Annual actuarial assumption review & other insurance adjustments 4 Adjusted earnings, ex. total notable items, by segment 5 Variable investment income (VII) 6 Investments 8 Direct expense ratio 9 Value of new business 10 Cash & capital 11 Appendix 12


 
3 Net income (loss) to adjusted earnings 3Q24 (post-tax) $ in millions $ per share1 Net Income (Loss) $1,275 $1.81 Less: Net Investment Gains (Losses) (61) (0.09) Net Derivative Gains (Losses)2 605 0.86 Market Risk Benefit Remeasurement Gains (Losses)2 (424) (0.60) Actuarial Assumption Review and Other Insurance Adjustments2 (6) (0.01) Investment Hedge Adjustments (102) (0.14) Other (112) (0.16) Adjusted Earnings $1,375 $1.95 Less Notable Items: Actuarial Assumption Review and Other Insurance Adjustments 16 0.02 Adjusted Earnings ex. Total Notable Items $1,359 $1.93 1 The per share data for each item is calculated on a standalone basis and may not sum to the total. 2 The Actuarial Assumption Review and Other Insurance Adjustments line item reflecting $6 million of after-tax losses includes $5 million of after-tax market risk benefit remeasurement losses and $1 million of after-tax net derivative losses. These amounts are therefore not included in the Net Derivative Gains (Losses) or Market Risk Benefit Remeasurement Gains (Losses) line items.


 
4 • Group Benefits: – Liability refinement related to an annuity payout feature on a small subset of Group Life portfolio – No ongoing impact • RIS: Favorable impacts from higher mortality in recent years • Asia: – Unfavorable changes to lapse assumptions in Japan – Lower expected fund returns for variable life products in Korea – Positive impact from improved morbidity in Japan and Korea 3Q24 annual actuarial assumption review and other insurance adjustments 1 Retirement and Income Solutions. 2 The per share data for each item is calculated on a standalone basis and may not sum to the total. HighlightsImpact


 
5 ($ in millions - except per share data) 3Q24 3Q23 % Change % Change (Constant Rate) Key Drivers1 Favorable Unfavorable Group Benefits $431 $483 (11%) Underwriting Margins RIS 368 409 (10%) Volume Growth; Underwriting Margins Investment Margins Asia 347 369 (6%) (5%) Underwriting Margins Investment Margins Latin America 217 199 9% 21% Equity Markets; Volume Growth EMEA 75 70 7% 9% Volume Growth MetLife Holdings 170 206 (17%) Foregone earnings2 Corporate & Other (249) (262) Expenses Investment Margins; Taxes Adjusted Earnings ex. Total Notable Items $1,359 $1,474 (8%) (6%) Adjusted EPS ex. Total Notable Items $1.93 $1.95 (1%) 1% Adjusted earnings, ex. total notable items, by segment 1 To be discussed on MetLife, Inc.'s third quarter 2024 earnings conference call and audio webcast. 2 As a result of reinsurance transaction with Global Atlantic Financial Group being effective in November 2023.


 
6 $179 $63 $260 $298 $162 3Q23 4Q23 1Q24 2Q24 3Q24 3Q24 VII decline due to lower private equity returns; real estate returns improve1 ($ in millions - pre-tax) Private Equity Other 1 Quarterly target VII range of $375 million, based on full year 2024 guidance range of ~ $1.5 billion. $0


 
7 ($ in millions - post-tax1) 3Q23 4Q23 1Q24 2Q24 3Q24 Group Benefits $1 $1 $4 $3 $2 RIS 35 23 73 64 50 Asia 37 10 56 99 44 Latin America 5 4 1 2 8 EMEA — — — — — MetLife Holdings 35 23 55 46 29 Corporate & Other 28 (11) 16 21 (5) Total Variable Investment Income $141 $50 $205 $235 $128 1 Assumes a 21% U.S. statutory tax rate. VII by segment


 
8 FY21 FY22 FY23 3Q23 3Q24 Net investment income: Higher asset growth offset by lower income from interest rate caps ($ in billions) Recurring income VII Net Investment Income1 $16.7 $5.7 Roll Off vs. Reinvestment $15.6 $1.5 New Money Yield Roll Off Yield 10-Year Treasury Yield 3Q21 1Q22 3Q22 1Q23 3Q23 1Q24 3Q24 1% 2% 3% 4% 5% 6% 7% 6.00% 5.78% 3.78% 1 As reported, on an adjusted basis. 2 Each item is calculated on a standalone basis and may not sum to the total. $21.3 $18.2 $5.1 $19.3 $0.4 $19.7 $4.9 $0.2 $5.0 $5.1 $0.2 2


 
9 12.2% 11.9% 11.9% 11.7% FY23 1Q24 2Q24 3Q24 1 Direct expense ratio, excluding total notable items related to direct expenses and pension risk transfers (PRT). 12.3% Annual Target 3Q24 direct expense ratio1 of 11.7%, below 12.3% annual target


 
10 1 Excludes MetLife Holdings; Value of New Business is the present value of future profits net of the cost of capital and time value of guarantees from new sales. Value of new business1 $3.8 $3.2 $2.8 $3.7 $3.6 $1.8 $1.9 $1.9 $2.3 $2.6 Capital Deployed Value of New Business 2019 2020 2021 2022 2023 ($ in billions) Internal Rate of Return Payback Period 15% 7 Years 17% 6 Years 17% 6 Years 17% 6 Years 19% 5 Years


 
11 Holding Company Cash1 $4.9 $5.2 $5.2 $4.4 $4.5 3Q23 4Q23 1Q24 2Q24 3Q24 Cash & capital 1 Includes cash and liquid assets at MetLife, Inc. and other holding companies at quarter-end. 2 Includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company for both periods. $3.0B to $4.0B Cash Buffer Capital ($ in billions) • Share repurchases of ~$0.8 billion in 3Q24 – ~$130 million shares repurchased in October 2024 • Expected total U.S. Statutory Adjusted Capital2 of $17.6 billion at 9/30/24, down 2% from 6/30/24 • Expected Japan Solvency Margin ratio of ~745% at 9/30/24


 
Appendix


 
13 • Concentrated in high quality assets and in larger primary markets • 68% average Loan-to-Value (LTV) Ratio and 2.2x average Debt Service Coverage Ratio (DSCR) – 77% of CML portfolio with LTVs less than or equal to 80% – 95% of CML portfolio with DSCRs greater than or equal to 1x – 79% average office LTV ratio and 2.1x average DSCR 1At September 30, 2024. All references to commercial mortgage loans in this earnings presentation are to net commercial mortgage loans, consisting of commercial mortgage loans, excluding commercial mortgage loans originated for third parties and related allowance for credit loss. LTV and DSCR Matrix $50.5 Billion DSCR LTV >1.2x 1.0-1.2x <1.0x Total <65% 46.2% 2.3% 2.0% 50.5% 65-75% 17.9% 1.3% 0.3% 19.5% 76-80% 6.8% 0.3% —% 7.1% >80% 15.8% 4.0% 3.1% 22.9% Total 86.7% 7.9% 5.4% 100.0% High quality commercial loans (CML) portfolio1


 
14 Cautionary Statement on Forward-Looking Statements The forward-looking statements in this presentation, using words such as “anticipate,” “are confident,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms, are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements.


 
15 Explanatory Note on Non-GAAP and Other Financial Information Any references in this presentation (except in this Explanatory Note on Non-GAAP Financial Information and Reconciliations) to: Should be read as, respectively: (i) net income (loss); (i) net income (loss) available to MetLife, Inc.’s common shareholders; (ii) net income (loss) per share; (ii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (iii) adjusted earnings; and (iii) adjusted earnings available to common shareholders; and (iv) adjusted earnings per share. (iv) adjusted earnings available to common shareholders per diluted common share. In this presentation, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). MetLife believes that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of the business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment. The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP: Non-GAAP financial measures: Comparable GAAP financial measures: (i) adjusted premiums, fees and other revenues; (i) premiums, fees and other revenues; (ii) adjusted premiums, fees and other revenues, excluding PRT; (ii) premiums, fees and other revenues; (iii) adjusted capitalization of deferred policy acquisition costs (DAC); (iii) capitalization of DAC; (iv) adjusted earnings available to common shareholders; (iv) net income (loss) available to MetLife, Inc.’s common shareholders; (v) adjusted earnings available to common shareholders, excluding total notable items; (v) net income (loss) available to MetLife, Inc.’s common shareholders; (vi) adjusted earnings available to common shareholders per diluted common share; (vi) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (vii) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share; (vii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (viii) adjusted other expenses; (viii) other expenses; (ix) adjusted other expenses, net of adjusted capitalization of DAC; (ix) other expenses, net of capitalization of DAC; (x) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses; (x) other expenses, net of capitalization of DAC; (xi) adjusted expense ratio; (xi) expense ratio; (xii) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT; (xii) expense ratio; (xiii) direct expenses; (xiii) other expenses; (xiv) direct expenses, excluding total notable items related to direct expenses; (xiv) other expenses; (xv) direct expense ratio; (xv) expense ratio; (xvi) direct expense ratio, excluding total notable items related to direct expenses and PRT; and (xvi) expense ratio; and (xvii) free cash flows of all holding companies. (xvii) MeLife, Inc. (parent company) net cash provided by (used in) operating activities.


 
16 MetLife’s definitions of non-GAAP and other financial measures discussed in this presentation may differ from those used by other companies: Adjusted earnings and related measures • adjusted earnings; • adjusted earnings available to common shareholders; • adjusted earnings available to common shareholders, excluding total notable items; • adjusted earnings available to common shareholders per diluted common share; • adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and • adjusted earnings available to common shareholders on a constant currency basis. These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results. Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends. Adjusted revenues and adjusted expenses These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP. Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments. Explanatory Note on Non-GAAP and Other Financial Information (Continued) Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the current period and applied to the comparable prior period (“constant currency basis”). Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this presentation and in this period’s earnings news release, which is available at www.metlife.com.


 
17 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments"). • Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance. • Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation- indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts. • Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance. Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP. Other adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs"). • Other revenues include fee revenue on synthetic guaranteed interest contracts ("GICs") accounted for as freestanding derivatives. • Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements. • Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives. Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance. The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms. In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium, which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders. Investment portfolio gains (losses) and derivative gains (losses) These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).


 
18 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Return on equity and related measures • Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, net of income tax. • Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, and total notable items, net of income tax. • Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.'s average common stockholders’ equity. • Adjusted return on MetLife, Inc.’s common stockholders’ equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity. • Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity, excluding AOCI other than FCTA. • Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA). The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses. Expense ratio, direct expense ratio, adjusted expense ratio and related measures • Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues. • Direct expense ratio: adjusted direct expenses, divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third-party staffing costs, and general and administrative expenses. • Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT. • Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues. • Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT. General Account (GA) assets under management (GA AUM) GA AUM is used by MetLife to describe assets in its GA investment portfolio. GA AUM is stated at estimated fair value and is comprised of GA total investments, the portion of the GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities fair value option securities, mortgage loans originated for third parties, assets subject to reinsurance arrangements with third-party reinsurers, and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties (“net mortgage loans”) (including commercial (“net commercial mortgage loans”), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. Classification of GA AUM by sector is based on the nature and characteristics of the underlying investments which can vary from how they are classified under GAAP. Accordingly, the underlying investments within certain real estate and real estate joint ventures that are primarily net commercial mortgage loans (at net asset value, net of deduction for encumbering debt) have been reclassified to exclude them from real estate equity and include them as net commercial mortgage loans. Asia GA AUM and related measures Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio. Asia GA AUM is stated at estimated fair value and is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties, assets subject to reinsurance arrangements with third-party reinsurers, and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties ("net mortgage loans") (including commercial ("net commercial mortgage loans"), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM. Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on net mortgage loans (including net commercial mortgage loans, net agricultural mortgage loans and residential mortgage loans) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.


 
19 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Statistical sales information: • Group Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products. • Retirement and Income Solutions: calculated using 10% of single premium contracts, on and off-balance sheet deposits, and the contract value for new UK longevity reinsurance contracts, and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance. • Latin America, Asia and EMEA: calculated using 10% of single premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group). Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity. The following additional information is relevant to an understanding of MetLife’s performance results and outlook: • Volume growth, as discussed in the context of business growth, is the period over period percentage change in adjusted earnings available to common shareholders attributable to adjusted premiums, fees and other revenues and assets under management levels, applying a model in which certain margins and factors are held constant. The most significant of such items are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates. • MetLife uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. MetLife defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders. • Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. • Holding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block. • We refer to observable forward yield curves as of a particular date in connection with making our estimates for future results. The observable forward yield curves at a given time are based on implied future interest rates along a range of interest rate durations. This includes the 10-year U.S. Treasury rate which we use as a benchmark rate to describe longer-term interest rates used in our estimates for future results.


 
20 Reconciliation of Net Income (Loss) Available to MetLife, Inc.'s Common Shareholders to Adjusted Earnings Available to Common Shareholders 3Q24 3Q23 Earnings Per Weighted Average Common Share Diluted1 Earnings Per Weighted Average Common Share Diluted1 (In millions, except per share data) Net Income (loss) available to MetLife, Inc.'s common shareholders $ 1,275 $ 1.81 $ 422 $ 0.56 Adjustments from net income (loss) available to MetLife, Inc.'s common shareholders to adjusted earnings available to common shareholders: Less: Net investment gains (losses) (77) (0.11) (927) (1.23) Less: Net derivative gains (losses) 767 1.09 (1,202) (1.59) Less: Market risk benefit remeasurement gains (losses) (531) (0.75) 796 1.05 Less: Other adjustments to net income (loss) (65) (0.09) (156) (0.20) Less: Provision for income tax (expense) benefit (195) (0.28) 429 0.57 Add: Net income (loss) attributable to noncontrolling interests (1) — 6 0.01 Adjusted earnings available to common shareholders 1,375 1.95 1,488 1.97 Less: Total notable items 16 0.02 14 0.02 Adjusted earnings available to common shareholders, excluding total notable items $ 1,359 $ 1.93 $ 1,474 $ 1.95 Adjusted earnings available to common shareholders on a constant currency basis $ 1,375 $ 1.95 $ 1,463 $ 1.94 Adjusted earnings available to common shareholders, excluding total notable items, on a $ 1,359 $ 1.93 $ 1,449 $ 1.92 constant currency basis Weighted average common shares outstanding - diluted 703.7 755.5 1Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share is calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.


 
21 Reconciliation to Adjusted Earnings Available to Common Shareholders, Excluding Total Notable Items 3Q24 Group Benefits1 Retirement & Income Solutions1 Asia Latin America EMEA MetLife Holdings1 Corporate & Other1 (In millions) Adjusted earnings available to common shareholders $ 373 $ 472 $ 306 $ 221 $ 70 $ 182 $ (249) Less: Total notable items (58) 104 (41) 4 (5) 12 — Adjusted earnings available to common shareholders, excluding total notable items $ 431 $ 368 $ 347 $ 217 $ 75 $ 170 $ (249) Adjusted earnings available to common shareholders, on a constant currency basis $ 306 $ 221 $ 70 Adjusted earnings available to common shareholders, excluding total notable items on a constant currency basis $ 347 $ 217 $ 75 3Q23 Group Benefits1 Retirement & Income Solutions1 Asia Latin America EMEA MetLife Holdings1 Corporate & Other1 (In millions) Adjusted earnings available to common shareholders $ 510 $ 470 $ 275 $ 199 $ 88 $ 208 $ (262) Less: Total notable items 27 61 (94) — 18 2 — Adjusted earnings available to common shareholders, excluding total notable items $ 483 $ 409 $ 369 $ 199 $ 70 $ 206 $ (262) Adjusted earnings available to common shareholders, on a constant currency basis $ 271 $ 179 $ 87 Adjusted earnings available to common shareholders, excluding total notable items on a constant currency basis $ 365 $ 179 $ 69 1Results on a constant currency basis are not included as constant currency impact is not significant.


 
22 Reconciliation of Net Investment Income to Adjusted Net Investment Income FY21 FY22 FY23 3Q23 3Q24 (In millions) Net investment income $ 21,395 $ 15,916 $ 19,908 $ 4,825 $ 5,227 Less: Adjustments to net investment income Investment hedge adjustments (895) (976) (1,012) (232) (129) Unit-linked contract income 952 (1,298) 1,183 4 147 Other adjustments (9) (10) (12) (3) 66 Divested businesses 67 11 — — — Adjusted net investment income $ 21,280 $ 18,189 $ 19,749 $ 5,056 $ 5,143


 
23 Reconciliation of Premiums, Fees and Other Revenues to Adjusted Premiums, Fees and Other Revenues FY23 1Q24 2Q24 3Q24 (In millions) Premiums, fees and other revenues $ 51,961 $ 11,975 $ 13,547 $ 12,523 Less: Adjustments to premiums, fees and other revenues: Asymmetrical and non-economic accounting 29 39 35 50 Other adjustments (34) (12) (11) (14) Divested businesses — — — 16 Adjusted premiums, fees and other revenues $ 51,966 $ 11,948 $ 13,523 $ 12,471


 
24 Expense Detail and Ratios FY23 1Q24 2Q24 3Q24 (In millions, except ratio data) Reconciliation of Capitalization of DAC to Adjusted Capitalization of DAC Capitalization of DAC $ (2,917) $ (740) $ (683) $ (691) Less: Divested businesses — — — — Adjusted capitalization of DAC $ (2,917) $ (740) $ (683) $ (691) Reconciliation of Other Expenses to Adjusted Other Expenses Other expenses $ 12,656 $ 3,191 $ 3,113 $ 3,188 Less Adjustments to other expenses: Other adjustments 55 7 5 12 Divested businesses 38 4 4 17 Adjusted other expenses $ 12,563 $ 3,180 $ 3,104 $ 3,159 Other Detail and Ratios Other expenses, net of capitalization of DAC $ 9,739 $ 2,451 $ 2,430 $ 2,497 Premiums, fees and other revenues $ 51,961 $ 11,975 $ 13,547 $ 12,523 Expense ratio 18.7 % 20.5 % 17.9 % 19.9 % Direct expenses $ 5,808 $ 1,426 $ 1,397 $ 1,392 Less: Total notable items related to direct expenses 96 — — — Direct expenses, excluding total notable items related to direct expenses $ 5,712 $ 1,426 $ 1,397 $ 1,392 Adjusted other expenses $ 12,563 $ 3,180 $ 3,104 $ 3,159 Adjusted capitalization of DAC (2,917) (740) (683) (691) Adjusted other expenses, net of adjusted capitalization of DAC $ 9,646 $ 2,440 $ 2,421 $ 2,468 Less: Total notable items related to adjusted other expenses 96 — — — Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses $ 9,550 $ 2,440 $ 2,421 $ 2,468 Adjusted premiums, fees and other revenues $ 51,966 $ 11,948 $ 13,523 $ 12,471 Less: PRT 5,324 (25) 1,752 529 Adjusted premiums, fees and other revenues, excluding PRT $ 46,642 $ 11,973 $ 11,771 $ 11,942 Direct expense ratio 11.2 % 11.9 % 10.3 % 11.2 % Direct expense ratio, excluding total notable items related to direct expenses and PRT 12.2 % 11.9 % 11.9 % 11.7 % Adjusted expense ratio 18.6 % 20.4 % 17.9 % 19.8 % Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT 20.5 % 20.4 % 20.6 % 20.7 %